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ABSTRACT
Huntington's disease (HD) is a progressive degenerative neurological disorder.
Individuals who inherit the IT15 gene with an expansion of the CAG repeat region inevitably
succumb to increasingly sever motor, psychological, and cognitive symptoms. I sought to
develop an assay system with the capability for identification of chemical compounds that
selectively decrease the intracellular levels of disease-causing expanded polyglutamine
huntingtin (Htt) protein without reducing the intracellular levels of the potentially protective
normal Htt. To achieve this goal I designed a cell-based assay using the enzymatic activity of E.
coli 1-galactosidase as a reporter for Htt protein levels. I expressed either expanded (97Q) or
normal (23Q) Htt fused to the 3-galactosidase alpha-subunit (a) in an inducible fashion in PC12
cells which also expressed the -galactosidase delta-subunit (A). Complementation between
these expressed subunits allowed the formation of functional 3-galactosidase. The level of
3-galactosidase activity in these A-a 97Q and A-a 23Q cells directly correlated with the amount
of a 97Q and a 23Q fusion protein levels, indicating that -galactosidase activity could be used
as a reporter in this system for Htt protein levels. I implemented this cell-based assay as a
secondary assay to characterize a group of compounds that had been initially identified in a High
Throughput Screen because they reduced levels of expanded Htt-fragment fused to GFP. Of the
34 compounds characterized in the -galactosidase A-a 97Q assay, dose response curves and
counter-screening with A-a 23Q cells revealed that seven compounds decrease 3-galactosidase
activity only in A-a 97Q cells. Immunofluorescence demonstrated that two compounds decrease
levels of expanded but not normal Htt proteins in the cells. Finally, tests of toxicity on HttQ103
PC12 cell lines, which show specific toxicity following expression of expanded Htt, revealed a
significant correlation with the results from the f3-galactosidase assay and the identification of at
least one compound which continued to meet the criteria for therapeutic intervention in HD.
These results support the feasibility of the development of an HD therapeutic strategy based on
small molecules which cause a specific reduction of intracellular expanded Htt protein levels and
suggest a program of development for such molecules.
Thesis Supervisor: David E. Housman
Title: Ludwig Professor of Biology
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CHAPTER I
HUNTINGTON'S DISEASE AND THE SEARCH FOR A TREATMENT
In 1872, George Huntington first published a description of a hereditary form of chorea
[1], the disease which now bears his name. He noted three hallmarks of Huntington's disease
(HD), aside from chorea: 1. Psychological symptoms: high likelihood of suicide, insanity, and
socially unacceptable behavior; 2. Dominant inheritance: affected individuals have an afflicted
parent; the lineage of children from an unaffected parent who do not manifest the disease also
never exhibit symptoms; 3. Late-onset: patients typically begin showing symptoms at 30-40
years of age.
Even though Huntington did not think that these observations were "of any great practical
importance", and presented the information "merely as a medical curiosity", HD is now a
recognized disease affecting 5-10 out of 100,000 people. The tremendous effort put forth by the
scientific community, particularly since the discovery of the gene responsible for the disease in
1993, has lead to a detailed understanding of the disease's cellular mechanisms. This knowledge
has in turn led to significant therapeutic promise. However, there is still no treatment for this
devastating disease.
HD SYMPTOMS IN MOVEMENT, PSYCHOLOGY, AND COGNITION
HD is now characterized by the progressive degeneration in motor, psychological, and
cognitive abilities [2]. Typically, chorea begins in the hands and feet, expanding over the years
to the limbs and face, while increasing in intensity. The symptoms include inability to control
the tongue, eyelids, and eye movements. Many HD patients exhibit aggressiveness, apathy, and
depression. HD patients are five times more likely to commit suicide than the general
population. The decline in cognitive ability affects memory, attention, concentration, emotional
processing, spatial manipulation, and eventually dementia.
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HD IS A DOMINANTLY INHERITED DISEASE
The genetic cause for HD is an expansion of the CAG repeats in the first exon of the
HUNTINGTINgene, located on chromosome 4 [3, 4]. This expansion in CAG repeats translates
into an expanded poly-glutamine (polyQ) region in the huntingtin (Htt) protein. Unaffected
individuals have Htt with 6-35Q (normal Htt), while HD patients have Htt with 40-1OOQ
(expanded Htt). The variation in the polyQ expansion in patients correlates to age of onset,
where patients with a longer polyQ region have a tendency to present with symptoms earlier in
life [5]. However, there is no correlation between the length of the polyQ region and the rate of
disease progression.
HD ANIMAL MODELS
While physical symptoms are easily described in HD patients, the underlying causes of
the symptoms can not be studied in humans. In order to more closely study the disease
mechanism, many HD animal models have been created by expressing expanded Htt. No animal
model is a perfect recreation of the disease in humans, but each one does recapitulate some of the
motor, psychological, and cognitive dysfunctions. Furthermore, some of these animal models
are widely used to determine efficacy of potential drug therapies for HD.
Drosophila
Neurodegeneration [6-8], motor dysfunction, and premature death [2] are HD phenotypes
that have been recapitulated in Drosophila models. The abnormalities observed in ommatidia,
clusters of eight photoreceptor neurons that make up the Drosophila eye, serve as evidence of
neurodegeneration. Motor function can easily by assayed by observing the larva's path through
agar and the adult's flying or walking abilities. Finally, the three month life-span of normal adult
Drosophila provides a relatively quick way to determine premature death.
The N-terminal Htt Drosophila model expresses specifically in the eye the first 170 aa of
Htt with either 75Q or 120Q [9]. Up through the pupal stage, all animals have normal eyes,
indicating that expanded Htt expression does not affect the development of the ommatidia.
However, degeneration of the ommatidia is observed in Htt-120Q and Htt-75Q containing
animals, with onset at adulthood day 10 and 30, respectively. Throughout early development,
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the expression of Htt is cytoplasmic in both Drosophila lines. In the transition from pupa to
adulthood, the expression of Htt-120Q begins to shift towards the nucleus. By day 10, this
expression becomes punctated.
Another HD Drosophila model expresses the first 548 aa of Htt with 128Q [10]. When
the transgene is expressed specifically in the eye, the ommatidia degenerate during adulthood.
When the transgene is expressed in all neurons, abnormal motor functions are observed in larvae
and adults. This expression of Htt-128Q results in premature death. In this Drosophila model,
cytoplasmic but not nuclear aggregated Htt is found in the late larval stage.
These Drosophila models are beneficial for determining the efficacy of a potential HD
drug treatment for several reasons. First, the effects of a drug on the extent and timing of
ommatidia degeneration can easily be quantified, which could parallel the drug's effect on
neurodegeneration seen in humans [6-8]. Second, a delay or prevention of lethality is another
measure of a drug's efficacy that can easily be assessed, and potentially beneficial to humans.
Third, the short life-span and large number of progeny of Drosophila allows for statistically
significant data from such drug tests.
Mouse
Many aspects of HD have been recapitulated in mouse models, although no one model
shows all. The neurodegeneration observed in humans [6-8] can be studied in mice by
measuring whole-brain weight, or by counting nuclei. Motor dysfunction [2] can be studied by
multiple protocols. One popular protocol is the accelerating rotarod, where a mouse is placed on
a rotating rod and the latency to fall is noted. Other protocols include gait analysis and
quantification of limb clasping. Cognitive ability [2] can be assayed by protocols that require
learning and memory. One such protocol is the Morris water maze, where the mice must learn
and remember the location of a hidden platform in a pool of water. Another learning protocol is
the T-maze, where the mice must learn which arm of a T-shaped maze contains the food. The
weight loss observed in HD patients [11] can easily be measured in mice by noting daily body
weights. Finally, premature death can be measured.
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R6/2 and R6/1 mice
The R6/2 and R6/1 mice were the first HD mouse models [12]. They express exon one of
Htt and an expanded polyQ, where R6/2 mice have 150Q and R6/1 mice have 115Q. At 3-4
weeks of age, the R6/2 mice show dysfunction in cognitive abilities as assayed by the Morris
water maze and T-maze [13]. At eight weeks of age, motor dysfunction is visible in R6/2 mice
by rotarod, limb clasping, and gait abnormalities, whereas the onset for R6/1 mice is around 13
weeks of age [12]. R6/2 mice start to lose weight around eight weeks of age. R6/2 mice tend to
die between 13-15 weeks of age, while R6/1 mice live longer than one year. There is significant
loss in brain weight in 12 week old R6/2 mice and 18 week R6/1 mice [14], although this is due
to cell atrophy and not cell loss [15, 16]. Striatal and cortical aggregates are first visible in 3-4
week old R6/2 and eight week old R6/1 mice [17, 18].
The R6/2 mice are the most commonly used mouse model for testing the efficacy of
potential drugs for HD treatment, discussed in the next section. One reason for this is that
because of the early onset of symptoms, the drug trials are quick. This allows for a larger
number of animals in the drug trials resulting in good statistical analysis of data.
N171-820 mice
The N171-82Q mice express the first 171 aa of Htt with 82Q in neurons [19]. The first
HD-related symptom to manifest is weight loss at two months of age. The motor dysfunctions
manifest in rotarod, limb clasping, and gait abnormalities begin at three months. Finally, these
mice die at 5-6 or 8-11 months, depending on the line. The expanded Htt protein is found
diffusely in the nucleus of neurons, but also in aggregated form in the cortex and striatum.
Neurodegeneration is evident in the striatum.
The N1 71-82Q mice have been used to test several drug treatments for HD, discussed in
the next section. Although the onset of symptoms is later than in the R6/2 mice, the onset is a
relatively quick 2-3 months. This later onset and prolonged disease progression can be an
advantage because the disease mechanism being targeted might require a prolonged exposure to
a drug in order to see an effect.
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Full-length Htt mice
Two full-length expanded Htt mouse models, cDNA with 89Q [20] and YAC with 72Q
[21], have a similar time-line in the onset of symptoms. Although a small percentage of striatal
neurons have nuclear aggregates, there is significant cell loss in the striatum at 12 months of age.
Another full-length Htt mouse model with 128Q, YAC128, begins to fail at the rotarod test at six
months of age, and neuronal cell loss is observed at 12 months of age [22]. None of these
models are ideal for drug testing because of the late-onset of motor symptoms and
neuropathology. However, these mouse models should be used for potential drugs that target
full-length Htt, since R6/2 and N171-82Q mice only express N-terminal fragments of Htt.
Knock-in polyQ expansion of mouse Htt
The mouse homolog of the HD gene, Hdh, is 91% identical to the human gene, with exon
one having 100% homology [23, 24]. In order to examine the effects of expanded Htt with a
normal expression pattern and protein levels, multiple groups have inserted expanded polyQ
tracts into the endogenous mouse Hdh gene [25-34]. Knock-in mice with 150Q, 140Q and 109Q
have abnormal gait beginning at 12 months, 12 months, and 24 months, respectively [25-27].
The Hdh-150Q mice also exhibit limb clasping and rotarod dysfunctions by 12 months of age
[27]. Although none of the knock-in mice show neuronal loss, those with 72-80Q and 140Q do
have axonal atrophy at 17-22 months and 14 months of age, respectively [32, 33]. Aggregates
are visible only in the striatum of Hdh-94Q mice [34], whereas they are more widespread
throughout the brain in knock-in mice with 109Q, 140Q, or 150Q [26-28]. The differences
between the onset of symptoms in the different knock-in mouse lines are partially due to the
length of the polyQ tract. In addition, genetic modifiers in the different mouse strains used to
insert the polyQ tract can be another factor. Similar to the transgenic full-length mouse models,
these knock-in mice could be used to test drugs that target the full length Htt protein.
DYSFUNCTIONAL CELLULAR PROCESSES IN HD
Htt is widespread throughout the body, with the highest expression in the central nervous
system [35, 36]. In cellular and animal models of HD, the majority of dysfunctional processes
are attributed to a gain of function by expanded Htt, although loss of function of normal Htt also
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contributes. The levels of normal Htt are decreased in HD patients since they express normal Htt
from only one allele. The 50% reduction in normal Htt levels is not the sole cause of HD
symptoms since people with a deletion in chromosome 4 that includes the HUNTINGTINgene
do not exhibit symptoms of HD [37]. However, the levels of normal Htt in HD patients are even
further reduced due to sequestration by expanded Htt.
Greater understanding of the dysfunctional cellular processes in HD has led to the
identification of potential drug therapies, described below. However, to date, success in treating
HD has been minimal [38]. An underlying reason for this limited success may be that each drug
tested thus far has been directed towards a single cause of cellular dysfunction in HD, while as I
will discuss below, there are in fact multiple pathways which have been shown to contribute
significantly to cellular dysfunction in HD. So, even if a drug were to be maximally effective in
addressing a single cause of cellular dysfunction, additional pathways to cellular dysfunction
may remain active during treatment with such a drug, resulting in the continued presence and
progression of disease symptoms.
Increased cell death
Brains from HD patients are significantly smaller due to dramatic cell loss in the striatum
and partial loss in the cortex [6, 7]. MRI scans of individuals who were an average 22 years
away from the predicted age of onset show that the striatum is already smaller [8]. Cell death in
HD has been attributed to the specific mechanisms of excitotoxicity and apoptosis, along with
death due to general cellular dysfunction.
Excitotoxicity
Excitotoxicity refers to cell death caused by continuous excitatory stimulation of a
neuron, such as that caused by the binding of a high affinity agonist to glutamate-receptors
causing intracellular calcium concentrations to rise to toxic levels. Normal Htt directly binds to
the scaffold protein PostSynaptic Density-95 (PSD-95), and stabilizes it at the synapse while
expanded Htt has a lower affinity to PSD-95 resulting in a higher amount of PSD-95 available to
stimulate NMDA receptors [39]. Over-stimulated NMDA receptors have been reported in cell
lines expressing expanded but not normal Htt [40, 41].
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Inhibitors of the NMDA pathway can decrease the amount of calcium influx and have
had some benefits in treating HD. Remacemide is a glutamate antagonist that, in R6/2 mice,
increases survival by 16% while improving motor functions, brain pathology, and weight loss
[42]. Riluzole is a another glutamate antagonist that, in R6/2 mice, increases survival by 10%
while improving motor functions, brain pathology, and weight loss [43]. In a one year clinical
trial, riluzole poses a transient benefit on chorea, and a slightly more sustained effect on other
motor symptoms of HD patients [44]. Memantine is an NMDA receptor antagonist that, in a two
year clinical trial, seems to slow the disease progression in HD patients [45].
Apoptosis
Apoptosis is programmed cell death, mediated by activated caspases. Comparison of
TUNEL staining, an indicator of apoptosis, in HD patients and control brains indicates that there
is an increase in apoptosis in HD [46]. One apoptosis marker is the release of cytochrome c,
which can be induced by expanded Htt [47]. Expanded Htt also activates some caspases, which
may directly lead to cell death [48, 49]. In addition, Htt contains several caspase cleavage sites
at the N-terminus [50] and it has been reported that expanded Htt undergoes cleavage more
efficiently than normal Htt [51]. This finding may explain the abundance of N-terminal
expanded Htt fragments. The size of the expanded Htt fragments inversely correlated to toxicity
[52].
Several caspase inhibitors have been examined as potential HD treatments since they
prevent apoptosis. The caspase inhibitor zVAD-fmk increases survival by 25% while improving
motor functions, brain pathology, and weight loss in R6/2 mice [53]. Cystamine was identified
as a transglutaminase inhibitor, although it seems to function in HD mice by inhibiting caspase
activity [54]. In R6/2 mice, cystamine increase survival by 20% while improving motor
functions, brain pathology, and weight loss [55, 56]. Minocycline inhibits activation of some
caspases by preventing cytochrome c release. R6/2 mice treated with minocycline survive 14%
longer while showing improvement in motor functions and brain pathology [57]. In a two year
clinical trial, minocycline stabilizes both motor and neurological symptoms [58].
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Toxicity
Many experiments have shown that normal Htt plays a protective role in cells. For
example, turning off the expression of normal Htt in the forebrain of a conditional knock-out
postnatal mouse leads to progressive neurodegeneration, behavioral abnormalities, and death
[59]. In cells, expression of normal Htt protects against multiple cellular insults that would
normally lead to apoptosis [60]. Normal Htt can also protect cells against the toxic effects of
expanded Htt, as over-expression of normal Htt in cells with expanded Htt results in a lower
incidence of cell death [61].
Mitochondrial activity
Brains of HD patients and pre-symptomatic individuals have a decrease in glucose
metabolism [62]. Interestingly, mitochondrial dysfunction is found specifically in the striatum
and cortex, whereas other brain areas are spared. Impaired mitochondrial activity causes
ineffective metabolism of glucose which can lead to damaging release of cytochrome c into the
cell [47]. Normal Htt is directly associated with mitochondrial membranes [63] and allows
proper transport of mitochondria along the axon, while expanded Htt prevents it [64]. Expanded
Htt also affects calcium levels, which can lead to mitochondrial dysfunction [65].
Some antioxidants mildly alleviate symptoms in HD mouse models. Alpha-lipoic acid
increases survival by 7% in both R6/2 and N171-82Q mice [66]. BN82451 improves survival by
15% while improving motor functions, brain pathology, and weight loss in R6/2 mice [67].
Dichloroacetate (DCA) activates mitochondrial activity, and in both R6/2 and N171-82Q mice, it
increases survival by 7% and improves motor functions, brain pathology, and weight loss [68].
Creatine is essential for normal mitochondrial function by stabilizing calcium levels and
its membrane permeability, and thus prevents the release of cytochrome c. In both R6/2 and
N171-82Q mice, creatine increases survival by 17% while improving motor functions, brain
pathology, and weight loss [69, 70]. Creatine given to symptomatic R6/2 mice decreases the
progression of symptoms, with the highest effects in younger, less symptomatic mice [71].
However, in a one year pilot clinical trial in humans, creatine had no effect on symptoms [72].
Coenzyme Q10 (CoQ 10) is an essential component of the electron transport chain, and an
antioxidant. In R6/2 mice, CoQ 10 increases survival by 15% while improving motor functions,
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brain pathology, and weight loss [42]. By combining CoQ10 with other active drugs, a higher
benefit has been seen in HD mouse models. CoQ 0 and minocycline in R6/2 mice increased
survival by 18% [73]. CoQ10 and remacemide resulted in an increase of 32% survival of R6/2
mice [42]. However, in a 2.5 year clinical trial, CoQ O10 alone or with remacemide had no effect
on symptoms in humans [74].
Transcriptional deregulation
Comparison of in situ hybridization in R6/2 and normal mice indicates that the mRNA
levels of several neurotransmitter receptors are decreased in HD [75]. Furthermore, extracts
from HD patient and mouse model brains have lower mRNA levels of several Neuron Restrictive
Silencer Element (NRSE)-controlled genes, including Brain Derived Neurotrophic Factor
(BDNF) [76]. Normal Htt, but not expanded Htt, allows the transcription of NRSE-controlled
genes by inactivating co-repressors of their transcription. One of the NRSE-responsive genes is
BDNF, which is transcribed in the cortex [77]. BDNF is an important protein in neuronal
activity because it acts as a neurotrophic factor, aiding in the formation or maintenance of the
cortico-striatal synapse.
Microarray data from HD mouse models [78], and human brains [79] show that the
transcription of many genes are decreased by the presence of expanded Htt. Expanded Htt can
sequester transcription factors and prevent the transcription of their targeted genes. A notable
example is CREB-Binding Protein (CBP) which is found in aggregates in HD cell and animal
models, along with brains from HD patients [80, 81]. CBP contains a polyQ region, the deletion
of which prevents it from being sequestered into aggregates. The expression of expanded Htt
leads to decreased transcription of CBP-dependent genes [82]. Replenishing the cells with the
transcription factors that have been sequestered may provide a benefit. For example, it has
recently been shown that increasing the levels of CBP in an HD Drosophila model completely
rescues neurodegeneration and transcriptional deregulation [83].
Another way expanded Htt decreases transcription is by reducing histone acetylation
[84]. Acetylated histones allow the transcription machinery to access the DNA, while
deacetylated histones impede this process. Several histone deacetylase inhibitors have been
tested in HD animal models. SuberoylAnilide Hydroxamic Acid (SAHA) and sodium butyrate
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(NaBu) rescue some of the neurodegeneration seen in an HD Drosophila model [85]. In R6/2
mice, SAHA alleviates some of the motor functions but has no effect on survival [86]. NaBu
increases survival by 22% while improving motor functions and brain pathology in R6/2 mice
[87]. Phenylbutyrate increases survival by 23% while improving brain pathology in the
N171-82Q mice [88]. Another way to globally increase transcription is to reduce histone
methylation, as mithramycin can do. In R6/2 mice, mithramycin increases survival by 29%
while improving motor functions and brain pathology [89].
Decreased protein trafficking
Many of the proteins that are involved in protein trafficking have altered expression
levels in HD [78, 79]. Normal Htt is associated with vesicle membranes, dendrites, axons, and
microtubules [36] and plays a role in vesicular transport between the axon and cell body [64, 90].
BDNF is an example of a protein whose transport via the microtubules is mediated by normal Htt
[91]. Expanded Htt reduces protein trafficking by sequestering many of the proteins involved in
protein trafficking, as well as binding to microtubules to prevent transport.
Decreased protein degradation
Proteins tagged with ubiquitin are targeted for degradation via the proteasome, and the
existence of ubiquitinated expanded Htt in aggregates suggests a dysfunction in this process [92].
The proteasome is inefficient in fully degrading ubiquitinated expanded Htt, resulting in the
release of small fragments containing the polyQ region [93]. Furthermore, inhibition of the
proteasome increases aggregates in a cell model [94], and prevents the clearance of expanded Htt
in a conditional mouse model [95]. In addition, cells that express expanded Htt are less able to
degrade Green Fluorescent Protein (GFP) tagged for proteasomal degradation [96], indicating
that proteasomal dysfunction affects more than just the expanded Htt protein.
In addition to the proteasome, Htt has been shown to be degraded by lysosome-mediated
autophagy. The inhibition of the proteasome seen in an HD cell model can be rescued by
activation of autophagy [97]. Rapamycin sequesters mTOR which causes an activation of the
autophagy degradation pathway. Rapamycin decreases neurodegeneration in an HD Drosophila
model, and improves motor functions in an HD mouse model [98].
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TOXIC FORM OF EXPANDED HTT IS STILL DEBATED
Although the loss of function of normal Htt contributes to HD symptoms by affecting
several cellular processes, its loss alone is not enough to explain the extent of the dysfunctions.
In a conditional mouse model, the complete loss of normal Htt in the forebrain of post-natal mice
leads to only some characteristic HD symptoms [59]. However, Htt is an essential protein during
development as best shown by three independently derived Htt knock-out mice, that all die in
gestation [99-101]. The fact that HD patients homozygous for the disease allele survive to
adulthood and do not exhibit an earlier age of onset relative to heterozygous patients [102],
indicates that expanded Htt can fulfill the developmental role of normal Htt.
It must therefore be the gain of function by expanded Htt that causes most of the cellular
dysfunctions. The question of which form, whether aggregated or monomeric, of expanded Htt
is the toxic species is still debatable. A direct pathway to the development of therapeutic
interventions aimed at specifically eliminating or reducing the formation of the toxic forms of
expanded Htt protein is currently challenging, since it is unclear which form should be targeted.
Aggregates
Aggregates of expanded polyQ Htt, visible in pathological specimens in the form of
inclusion bodies, are evident in diseased brains, but not control brains [6, 7]. Patients with
longer polyQ regions have a higher prevalence of inclusion bodies containing aggregated Htt
[103], particularly in the cortex [104]. In the nuclei of neurons, the aggregated Htt consists of
small N-terminal fragments of expanded Htt, while in the cytoplasm aggregated Htt includes
variably sized N-terminal expanded Htt fragments [104]. Both expanded and normal Htt are
cleaved at multiple sites by caspases [50, 105], although expanded Htt is preferentially cleaved
[51]. Expanded Htt nucleates into aggregates faster than normal Htt, where the rate-limiting step
is believed to be a change in protein conformation [106]. In addition, the smaller the Htt
fragment, the faster expanded Htt forms aggregates.
In support of the toxic aggregates theory, pure polyQ aggregates which were created in
vitro and then introduced to cells cause toxicity when the aggregates are targeted to the nucleus
[107]. However, these polyQ aggregates are very stable whereas aggregates in HD cell and
animal models are dynamic. Since caspase cleavage of Htt results in the elimination of the C-
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terminal Nuclear Export Signal [108], nuclear toxicity is a possible role for aggregated or
monomeric expanded Htt. In addition, proteins such as chaperones, proteasome subunits,
transcription regulating proteins, and ubiquitin binding proteins are sequestered by monomeric
expanded Htt and found in aggregates. The loss of function of these proteins can lead to cellular
dysfunction.
Some aggregation inhibitors have had some benefit in HD animal models. The
compound C2-8 partially rescues neurodegeneration in an HD Drosophila model [109]. C4-sFv
is a single-chain Fv antibody fragment that rescues larval survival and delays neurodegeneration
in an HD Drosophila model [110, 111]. Congo Red inhibits oligomerization and, in R6/2 mice,
increases survival by 16% while improving motor functions, brain pathology, and weight loss
[112]. Trehalose is a disaccharide that inhibits aggregation by stabilizing proteins in a partially-
folded state [113]. In R6/2 mice, trehalose increases survival by 11% while improving motor
functions, brain pathology, and weight loss [114].
Monomeric
An alternative to expanded Htt aggregates having detrimental effects in cells is that
aggregates benefit cells by sequestering toxic monomeric Htt and thus prevent it from interfering
in cellular processes. Support for the beneficial aggregates theory comes from the fact that
aggregates are mainly found in striatal and cortical cell types that are spared in HD, while those
cell types that tend to die have fewer aggregates [115]. In general, aggregate density does not
correlate with cell loss, as perhaps best shown in the brain of one pre-symptomatic individual
which had many aggregates in the cortical region but very little cell loss [116]. Further support
comes from the full rescue of motor functions, in spite of continued presence of aggregates,
following arrest of expanded Htt expression in a 17 month old conditional mouse model [117].
Most recently, a compound was identified that rescues proteasome dysfunction in an HD cell
model by increasing aggregate formation [118]. Direct and compelling support for the protective
effect of intracellular inclusions and the toxic effects of soluble expanded Htt species is provided
by time lapse cinematography of cultured neurons in an Htt model system. In this study,
neurons, that show a diffuse signal for expanded Htt are more likely to die while under
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observation than neurons that have aggregated expanded Htt in the form of inclusion bodies
[119].
COULD REMOVAL OF DISEASE-CAUSING EXPANDED HTT BE AN OPTIMAL
THERAPY FOR HD?
Drugs targeted at cellular dysfunctions or expanded Htt aggregation have not provided
sufficient benefit in ameliorating HD symptoms to be considered an effective treatment. In order
to evaluate the effect of removing expanded Htt after disease-onset, the conditional mouse model
HD94, where exon one of expanded Htt is expressed in the forebrain, was created [120]. When
the expression of expanded Htt is eliminated after onset of symptoms, the progression of motor
dysfunction and neuronal loss is not only prevented but the symptoms are actually reverted. If
the expression is turned off at 10 months of age, the motor dysfunction is completely rescued and
aggregates are no longer visible [121]. When the expression is turned off at 17 months of age,
motor dysfunction is also completely rescued, however in this case without any effect on
aggregates [117].
The study of the HD94 mouse model indicates that removal of the disease-causing
expanded Htt is a viable treatment for the disease which can be beneficial at multiple stages in
disease progression. One way to decrease the expanded Htt protein load is to prevent its
translation by the use of RNAi targeted to the striatum. RNAi treatment in N171-82Q mice
results in a 50% reduction of Htt mRNA for 2 weeks, while improving motor functions [122]. In
R6/1 mice, RNAi treatments cause an 80% decrease in Htt mRNA for 10 weeks, while delaying
the onset of motor symptoms [123]. RNAi treatments in R6/2 mice which decreased Htt mRNA
levels by about 50% for one week result in increased survival and improved motor functions,
brain pathology, and body weight [124]. RNAi treatment given after onset can also prevent the
progression of neuropathology [125]. These results with RNAi treatments are encouraging
because they show benefit even without complete elimination of expanded Htt. However, a
drawback to RNAi is that it can not be specific for expanded Htt because RNAi targets small
sections of mRNA sequence, which do not differ between expanded and normal Htt. Since
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normal Htt serves a protective role, it is not ideal for an HD treatment to decrease the levels of
normal Htt.
An approach to HD therapy which has the potential to address the occurrence of
pathology at its source would be to decrease the levels of expanded Htt while maintaining the
expression of normal Htt to maximize the protective effects of normal Htt. A compound could
decrease the levels of expanded Htt proteins by either reducing the efficiency of its initial
production or by promoting its degradation. The elimination of expanded Htt would allow cells
to recover from the cellular dysfiunctions caused by the expression of expanded Htt. Such a
compound would, in principle, not only prevent the onset of disease, but also stop the
progression of symptoms, as seen in the HD94 mouse model [120]. A therapy which met these
criteria would have no effect on the expression of normal Htt, allowing it to continue with its
protective cellular functions. The fact that expanded and normal Htt have different tertiary
structures [126] allows for the possibility that a chemical compound could have specificity to
expanded but not normal Htt. The goal of the study presented here was to design and implement
a cell-based High Throughput Screen that could identify a compound which met these criteria for
an optimally effective HD therapeutic. Therefore, the assay developed is designed to target the
most basic cause of HD, the expression of expanded Htt, while making no assumptions as to
which cellular dysfunction causes the most harm to HD patients or which form of expanded Htt
is the most toxic to cells. The results of this screen provide a proof of concept for this approach
through the identification of two compounds which decrease cellular levels of expanded but not
normal Htt protein. The efficacy of compounds in another cell-based assay based on the toxicity
caused by expanded Htt expression further validates this approach to therapeutic intervention.
These studies thus provide initial steps in a pathway towards a direct and potentially effective
approach to the treatment of HD.
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CHAPTER II
DESIGN AND PRODUCTION OF A CELL-BASED HTS FOR IDENTIFYING
COMPOUNDS WHICH DECREASE EXPANDED HTT PROTEIN LEVELS
ABSTRACT
Huntington's disease (HD) is a progressively degenerative neurological disorder.
Individuals who inherit the IT15 gene with an expansion of the CAG repeat region inevitably
succumb to motor, psychological, and cognitive symptoms. I sought to develop an assay system
with the capability for identification of chemical compounds that selectively decrease the
intracellular levels of disease-causing expanded polyglutamine huntingtin (Htt) protein without
reducing the intracellular levels of the potentially protective normal Htt. To achieve this goal I
designed a cell-based assay using the enzymatic activity of E. coli 3-galactosidase as a reporter
for Htt protein levels. I expressed either expanded (97Q) or normal (23Q) Htt fused to the
f3-galactosidase alpha-subunit (a) in an inducible fashion in PC 12 cells which also expressed the
3-galactosidase delta-subunit (A). Complementation between these expressed subunits allowed
the formation of functional -galactosidase. The level of -galactosidase activity in these
A-a 97Q and A-a 23Q cells directly correlated with the amount of a 97Q and a 23Q fusion
protein levels, indicating that P-galactosidase activity could be used as a reporter in this system
for Htt protein levels. Optimization of A-a 97Q cells for High Throughput Screening (HTS)
resulted in a Z' factor of 0.73. These data demonstrate that the cell based assay system I have
developed is well suited for the identification of chemical compounds which specifically
decrease intracellular expanded Htt protein levels in an HTS format.
25
INTRODUCTION
Huntington's disease (HD) is characterized by the progressive degeneration in motor,
psychological, and cognitive abilities [1, 2]. The genetic cause for this disease is an expansion of
the CAG repeats in the first exon of the IT15 gene, located on chromosome 4 [3, 4]. This
expansion in CAG repeats translates into an expanded poly-glutamine (polyQ) region in the
huntingtin (Htt) protein. Unaffected individuals have Htt with 6-35Q (normal Htt), while HD
patients have Htt with 40-1OOQ (expanded Htt). The variation in the polyQ expansion in patients
is correlated to age of onset, where patients with a larger polyQ region have a tendency to
present with symptoms earlier in life [5]. However, there is no correlation between the length of
the polyQ region and the rate of disease progression.
Htt is widespread throughout the body, with the highest expression in the central nervous
system [6, 7]. Expanded Htt has been implicated in decreasing mitochondrial activity [8-10],
transcription [11-18], and protein degradation [19-23]. Loss of normal Htt further contributes to
dysfunction in the mitochondria [9,24], transcription [25], and protein trafficking [9, 26-28].
The ultimate end to cellular dysfunction, cell death, has also been observed in HD.
Brains from both symptomatic and pre-symptomatic HD patients show a remarkable decrease in
striatal and cortical neurons [29-31]. There is some evidence suggesting apoptosis in the brain as
a mechanism for neuronal loss [32]. There is also evidence suggesting excitotoxicity as a
specific mechanism contributing to neuronal death [33-35]. Cell-based assays expressing exon
one of expanded Htt have been designed and implemented to screen for compounds that rescue
toxicity [36, 37]. These screens identified several compounds which decrease toxicity, although
the only class of compounds found by both screens is caspase inhibitors. An issue which must
be considered in such screens is that cellular dysfunction preceding cell death may lead to many
of the symptoms observed in patients. Thus, even if compounds identified by screens based on
blocking cytotoxicity suppress cell death in HD patients, they may not be effective treatments for
HD because they do not prevent cellular dysfunction.
The presence of inclusions containing aggregated expanded Htt in the brains of HD
patients [29, 30] has led to the hypothesis that these inclusions are responsible for the cellular
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dysfunction and death [38]. Many cell-based assays have been designed and implemented to
screen for aggregation inhibitors, whose endpoints are directly or indirectly tied to the formation
of intracellular inclusions. Several potent aggregation inhibitors have limited effects on survival
of HD animal models [39-41], indicating that inhibition of aggregation may not be the most
effective way to treat HD. The drawback to these aggregation screens is that they assume
inclusions are responsible for HD symptoms. Since there is evidence that inclusions may be
beneficial to cell survival [42], this assumption may not be correct.
Assays designed to identify compounds that target particular cellular functions, cell
death, and aggregation can only be used to screen for compounds that act in one specific disease
pathway. Since expanded Htt has been implicated in many cellular dysfunctions, the most
straight-forward way to treat HD would be to eliminate the disease-causing expanded Htt from
cells. In order to evaluate the effect of removing expanded Htt after disease-onset, the
conditional mouse model HD94, where exon one of expanded Htt is expressed in the forebrain,
was created [43]. When the expression of expanded Htt is eliminated after onset of symptoms,
the progression of motor dysfunction and neuronal loss is not only prevented but the symptoms
are actually reverted. If the expression is turned off at 10 months of age, the motor dysfunction
is completely rescued and aggregates are no longer visible [44]. However, if the expression is
turned off at 17 months of age, motor dysfunction is completely rescued without any effect on
aggregates [45]. The study of this mouse model indicates that blockage of the production of the
disease-causing expanded Htt is a viable treatment approach for the disease which can be
beneficial at multiple stages in disease progression.
The first attempt at treating HD by eliminating expanded Htt was the use of RNAi
treatments in various HD mouse models, which improves survival and motor functions while
decreasing neuropathology [46-48]. These results with RNAi treatments are encouraging
because they show benefit even without complete elimination of expanded Htt. However, a
drawback to RNAi is that it can not be specific for expanded Htt because RNAi targets small
sections of mRNA sequence, which do not differ between expanded and normal Htt. Since
normal Htt serves a protective role, it is not ideal for an HD treatment to decrease the levels of
normal Htt.
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The most effective way, in principle, to treat HD is to decrease the levels of expanded Htt
while maintaining the expression of normal Htt. The fact that expanded and normal Htt have
different tertiary structures [49] allows for the possibility that a compound could have specificity
for expanded but not normal Htt. Here, a cell-based assay was designed to identify compounds
which decrease the levels of expanded but not normal Htt proteins, making no assumptions as to
which cellular dysfunction causes the most harm to HD patients or which form of expanded Htt
is the most toxic to cells. This assay uses -galactosidase activity as a reporter for Htt protein
levels. PC12 cells expressing the O-galactosidase delta-subunit (A), and either expanded (97Q)
or normal (23Q) Htt fused to the -galactosidase alpha-subunit (a) in an inducible fashion exhibit
P-galactosidase activity. The level of P-galactosidase activity in these A-a 97Q and A-a 23Q
cells directly correlated with the amount of a 97Q and a 23Q fusion protein levels, indicating
that P-galactosidase activity could be used as a reporter for Htt protein levels. Furthermore,
these cells were optimized for High Throughput Screening.
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RESULTS
Assay design
A cell-based assay has been designed to identify small molecules that decrease the
amount of expanded huntingtin (Htt) but do not affect the levels of normal Htt. To accomplish
this task, this system exploits the sensitive and quantitative features of a Beta-galactosidase
(3-galactosidase) enzymatic activity assay reported elsewhere [50, 51]. The 3-galactosidase
enzyme consists of two functional domains, termed the delta (A) and alpha (a) subunits. The
f3-galactosidase A- and a-subunits are physically separable and enzymatically inactive when
expressed alone (Fig 1A). Restoration of functional P3-galactosidase activity is mediated by a
process known as alpha-complementation, successfully used in bacteriology, which occurs via
intracellular association of the A-subunit with the highly unstable a-subunit. Rapidly degraded
by cells, the small a-subunit can be stabilized when fused to Htt fragments (a Htt), which still
allows for P3-galactosidase activity. Thus, P-galactosidase activity is the reporter for the presence
of the Htt protein in this system.
The measurement of f-galactosidase activity is highly reproducible and quantitative,
making it possible for identification of compounds that decrease the protein levels of expanded
Htt to varying degrees. The ideal compound for treating Huntington's disease would be one
which targets expanded Htt but not normal Htt. Since in this system P-galactosidase activity
depends on the expression of both the 3-galactosidase A-subunit and a Htt fusion proteins, this
ideal compound would decrease the protein levels of expanded Htt fused to the f-galactosidase
a-subunit and thus abolish 3-galactosidase activity (Fig 1A). The specificity of this compound
would be identified by its ability to decrease 3-galactosidase activity in cells expressing
expanded Htt but not in cells expressing normal Htt.
For this assay, the 1-galactosidase a-subunit was cloned upstream of the first 600 aa of
Htt containing either 97Q for expanded Htt (a 97Q) or 23Q for normal Htt (a 23Q) (Fig B).
This size fragment of Htt was chosen because it contains all the known caspase cleavage sites
[52]. The advantage is that this fragment can undergo most if not all of the conformations that
full length Htt can, thus maximizing the types of compounds that can be identified in this screen
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which can differentiate between expanded and normal Htt. In order to control the timing and
level of expression of both the 3-galactosidase A-subunit and a Htt fusion proteins, constructs
were cloned under the control of an ecdysone inducible system, where Ponasterone A (PonA) is
used as the inducer.
Generation of stable PC12 cells
Before committing to generating stable cell lines, transient transfections were done on
CHO (Chinese hamster ovary) and PC 12 (rat pheochromocytoma) cells. In both cell types,
-galactosidase activity was only seen with co-transfection of the f3-galactosidase A-subunit and
either a 97Q or a 23Q constructs (data not shown). This verified that the constructs were able to
undergo alpha-complementation. For stable transfections, PC 12 cells were chosen because they
are a pre-neuronal cell line that can be differentiated into neuronal-like cells [53, 54].
In order to make stable cell lines that express both the 3-galactosidase A-subunit and the
a Htt fusion constructs, two rounds of stable transfections were performed. In the first step, the
-galactosidase A-subunit was stably transfected into PC 12 cells containing the expression
vector for the Ecdysone Receptor, EcR PC12 cells. Small colonies of these EcR-A cells were
individually picked and expanded. After 24 hr of induction with PonA, 3 out of 31 clones were
found to alpha-complement with transiently transfected a 23Q (Fig 2). Clone 600-2 was chosen
to continue with the next round of stable transfections because it most closely resembled the
morphology of the parental cell line.
The chosen EcR-A cell line was then stably transfected with either the a 97Q or a 23Q to
make A-a 97Q or A-a 23Q cells, respectively. Individual colonies were picked and expanded.
After 24 hr of induction with PonA, 3 out of 52 A-a 97Q clones and 5 out of 45 A-a 23Q clones
had P-galactosidase activity (Fig 3).
Selection of A-a 97Q and A-a 23Q cell lines for screen
The two rounds of stable transfections generated three A-a 97Q and five A-a 23Q cell
lines that showed varying degrees of -galactosidase activity after 24 hr of induction. Since the
A-a 23Q cell lines were to be used as a counter-screen for the A-a 97Q cell line, it was important
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to choose the A-a 97Q and A-a 23Q cell lines that most closely resembled each other. Therefore,
multiple characteristics were examined in order to make this choice: cell size, cell morphology
compared to the parental line, doubling time, percent of cells having P3-galactosidase activity
after induction, and amount of 13-galactosidase substrate hydrolyzed (Table 1). Cell lines
A-a 97Q #46 and A-a 23Q #44 were chosen due to their exact match in cell size, doubling time,
and substrate hydrolyzed. In addition, their cell morphology and percent of cells with
3-galactosidase staining were very similar. From here on, all experiments described were
performed on A-a 97Q #46 and A-a 23Q #44 cells, and are referred to as simply A-a 97Q and
A-a 23Q cells, respectively.
Induction with PonA correlates with P-galactosidase activity along with P-galactosidase
A and a Htt protein levels
The 0-galactosidase activity assay yields a colorimetric output, which is detected using
photometry and then converted to nmoles of substrate hydrolyzed. The effects of different levels
of induction of the 13-galactosidase A-subunit and a 97Q or a 23Q proteins on P3-galactosidase
activity were assessed by titration of the inducer PonA (Fig 4A). The amount of PonA directly
correlated with 3-galactosidase activity. Furthermore, Western blots showed that the protein
levels of P3-galactosidase A-subunit and a 97Q or a 23Q increased with the increase in PonA
(Fig 4B and C). These data show a direct correlation between the amount of PonA added and the
levels of 3-galactosidase activity detected in cell lysates, and demonstrate the sensitivity of this
assay to changes in 3-galactosidase A-subunit, a 97Q, or a 23Q protein levels.
A-a 97Q and A-a 23Q cells can degrade P-galactosidase A and a 97Q or a 23Q proteins
The purpose of this screen is to identify compounds that can decrease the protein levels
of expanded Htt but not normal Htt. One likely mechanism to accomplish this would be to
promote the degradation of the proteins. Therefore, it was important to show that A-a 97Q and
A-a 23Q cells were capable of degrading the induced a 97Q or a 23Q proteins on their own.
This was assessed by inducing cells with PonA for 24 hr. At this point, the medium was
removed from all wells and replaced with either medium without PonA (washed) or medium
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with PonA (un-washed). By 12 hr after removal of the inducer, the -galactosidase activity was
the same as un-induced (0 hr) cells (Fig 5A and B). At this time, the induced a 97Q and a 23Q
protein levels dramatically decreased, as well as the induced P3-galactosidase A-subunit protein
levels, although less so. By 24 hr after the removal of the inducer, Western blots show no
detectable a 97Q and a 23Q (Fig 5C and D) or P3-galactosidase A proteins (Fig 5E and F). This
shows that the lack of P3-galactosidase activity in the screen at 24 hr is an appropriate indication
of degradation of the a 97Q or a 23Q fusion proteins and/or the -galactosidase A-subunit.
Optimization of p-galactosidase assay for High Throughput Screen
It is important to maximize speed and reproducibility in a High Throughput Screen
(HTS). Therefore, several aspects of the f3-galactosidase assay were examined in order to find
the protocol which minimized the number of steps while maximizing the enzymatic read-out
(data not shown). The number of cells seeded per 96-well was maximized to ensure a high
f-galactosidase activity without over-seeding which could result in unhealthy cells. It was
determined that only a single PBS wash was needed to fully remove the media from the wells to
ensure reproducible results. Multiple recipes of lysis buffer were tested to find one which
minimized the background absorbance reading at 405 nm, maximized the detection of
f,-galactosidase activity, and minimized the amount of time needed for maximal 3-galactosidase
activity. It was determined that 30-45 min in 37°C resulted in an absorbance reading at 405 nm
near but not above 1.0, which is the limit of reliability. Finally, addition of STOP buffer after
this incubation allowed the -galactosidase signal to remain stable, giving flexibility in the
timing of plate reading.
A-a 97Q cell population has high Z' factor
These experiments showed that A-a 97Q and A-a 23Q cells are capable of reporting what
they were designed to do, namely use -galactosidase activity as a reporter for the protein levels
of a Htt. However, in order to be useful for an HTS, the P-galactosidase activity of the negative
and positive controls had to be significantly different for statistical analysis of the effect of
compounds. One way to measure this is with Z' factor, which takes into account the difference
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of the mean between two populations and the variance within each population (Fig 6). A Z'
factor higher than 0.2 is considered acceptable for HTS, while higher than 0.5 is desirable.
Using the optimized protocol for HTS, the Z' factor for A-a 97Q cell population was calculated
to be 0.73 under conditions for use in Aleksey Kazantsev's HTS laboratory at Massachusetts
General Hospital. These data indicate that A-a 97Q cells are highly suitable for HTS.
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DISCUSSION
Although Huntington's disease is known to be caused by the expression of the Htt protein
with expanded glutamines, it is still widely debated how this protein causes the vast spectrum of
symptoms in patients. Which of the cleaved Htt-fragments is most detrimental? Which role of
expanded Htt within a cell is the disease-causing role and which roles are non-consequential?
Does the disease mechanism best correlate with cellular dysfunction or cell death? While these
are all important and scientifically relevant questions to answer, designing a cell-based drug
screen founded on a potential disease-causing role for Htt is risky. For this reason, a drug screen
was designed based on the fact that the expression of expanded Htt is detrimental to cells,
making no assumptions as to which form or role of expanded Htt is responsible for the disease
mechanism.
The complexity of symptoms of Huntington's disease is a combination of gain-of-
function by expanded Htt and loss-of-function of normal Htt. For this reason, a counter-screen
was designed with normal Htt to rule out compounds that also decrease the protein levels of
normal Htt. This distinction is important because normal Htt has been shown to be protective in
cells [55-57]. The fact that expanded and normal Htt have different tertiary structures [49]
allows for the possibility of a compound to selectively recognize expanded but not normal Htt.
The cellular assay described here was designed using P3-galactosidase activity as a
reporter for the presence of expanded (97Q) or normal (23Q) Htt. Two cell lines were generated,
A-a 97Q and A-a 23Q, under an ecdysone inducible system. Induction with PonA directly
correlated with P3..galactosidase activity, and the protein levels of P3-galactosidase A-subunit and
a 97Q or a 23Q. In addition, the cells were able to degrade these induced proteins within 24 hr
after removal of inducer. Together, these sets of experiments show that the amount of
f-galactosidase activity (i.e., of -galactosidase substrate cleaved) correlates with the amount of
a 97Q or a 23Q present in cells and serves as an indicator of Htt clearance. Furthermore, these
results show that these cells are capable of clearing expanded Htt, recapitulating the clearance
observed in the inducible mouse model [43] of HD. This confirms that the cell lines possess an
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intrinsic mechanism for degrading expanded Htt, and validates this cell line for use in an HTS to
identify small molecules.
While this screen was designed to use P-galactosidase activity as a reporter for the
decrease in protein levels of expanded Htt, the loss of j3-galactosidase activity in this assay can
be caused by a number of different mechanisms. The compounds I particularly sought would
decrease the amount of expanded Htt protein, but not normal Htt. The decrease in protein may
be accomplished either in the production (transcription, translation) or degradation of protein.
The degradation of proteins can be increased by proteasome-targeting or affecting chaperones to
increase misfolding. The identification of a compound which differentially acted preferentially
on expanded Htt would be of particular significance because it would represent proof of principle
that this approach to therapeutic intervention in HD was technically feasible.
Regardless of the mechanism by which a compound specifically decreases levels of
expanded but not normal Htt, such a compound should also score positively in assays which
measure downstream consequences of expanded Htt function, including the inhibition of
aggregation and the rescue from toxicity in other cellular assays. Compounds of this type may be
helpful in sorting out the relationships among theories regarding which products of expanded Htt
are most significant in causing pathology.
If aggregates are toxic to cells, then reduction in aggregates would lead to a reduction in
cell death. Evidence to support the toxic aggregate theory comes from experiments where pure
polyQ aggregates taken up by cells causes toxicity when the aggregates are targeted to the
nucleus [58]. Since caspase cleavage of Htt results in the elimination of the C-terminal nuclear
export signal [59-1, nuclear toxicity is a possible role for aggregated expanded Htt. In addition,
sequestered proteins such as chaperones, proteasome subunits, transcription regulating proteins,
and ubiquitin binding proteins are found in aggregates. The loss of function of these proteins can
lead to cellular dysfunction, and ultimately cell death.
If the alternative theory that monomeric expanded Htt is toxic because it interferes in
cellular processes is true, then compounds that decrease levels of expanded but not normal Htt
protein would rescue toxicity because they eliminate the disease-causing protein. Support for the
toxic monomeric theory lies in the observation that neurons which show a diffuse signal for
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expanded Htt are more likely to die than neurons that have aggregated expanded Htt [60]. In this
theory, aggregates are actually protective because they sequester monomeric expanded Htt and
prevent it from doing further harm in a cell. Further support comes from the observation that
aggregates are mainly found in striatal and cortical cell types that are spared in HD, while those
cell types that tend to die have fewer aggregates [61]. In general, aggregate density does not
correlate with cell loss [62]. This is perhaps best shown in the brain of one pre-symptomatic
individual which had many aggregates in the cortical region but very little cell loss. Further
support comes from the full rescue of motor functions, in spite of continued presence of
aggregates, following arrest of expanded Htt expression in a conditional mouse model [45].
Most recently, compounds have been identified that rescue proteasome dysfunction in an HD cell
model by increasing aggregate formation [63].
Compounds identified in the A-a 97Q screen described here could fall into another
category, where the decrease in 3-galactosidase activity is caused by affecting the alpha-
complementation specifically in A-a 97Q but not A-a 23Q cells. Possible mechanisms would be
physical interference between the P3-galactosidase subunits, alteration of expanded Htt
conformation, or re-localization of expanded Htt to a different cellular compartment. All of
these could prevent alpha-complementation between the O3-galactosidase A-subunit and a 97Q
proteins. While these mechanisms themselves may not benefit the treatment of the disease, these
compounds could still be interesting because of their selectivity to expanded Htt but not normal
Htt. Study of these compounds could lead to knowledge of how they confer selectivity for
expanded Htt, which could be applied to other compounds that do promote degradation.
The final category of compounds that could be identified in this screen is one where
compounds are affecting common components of the two cell lines. These would be compounds
which decrease J3-galactosidase activity in both A-a 97Q and A-a 23Q cells by decreasing the
number of cells, decreasing any Htt protein levels, decreasing 03-galactosidase A-subunit levels,
or interfering with the ecdysone inducible system (preventing either PonA from binding to the
ecdysone receptor, or the ecdysone receptor from binding to E/GRE). While compounds that
decrease the protein levels of both expanded and normal Htt are not the focus of this screen,
these compounds could still be beneficial for drug development since medicinal chemistry may
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create a related compound that maintains the ability to decrease Htt protein levels, but makes it
specific to expanded Htt. However, the A-a 23Q counter-screen would be unable to differentiate
between compounds that decrease the protein levels of all Htt proteins and those that affect
common components between the two cell lines. Therefore, additional experiments would be
necessary to determine this information, discussed in Chapter IV.
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MATERIALS AND METHODS
Cloning
The P3-galactosidase A-subunit, lacking the first 500 bp of P3-galactosidase, was cloned
into a pIND vector (Invitrogen), which contains five E/GREs and a promoter for induction with
Ponasterone A. The 3-galactosidase a-subunit, the first 500 bp of 3-galactosidase, was cloned
upstream of the first 600 aa of Htt containing either 97Q or 23Q, with a FLAG-tag in between.
These constructs, a 97Q and a 23Q, were then cloned into a pIND/Hygro vector (Invitrogen),
containing five E/GREs and a promoter for induction with Ponasterone A.
Generation of stable PC12 cell lines
PC12 cells stably transfected with pVgRXR (Ecdysone Receptor expression vector), was
used as the parental cell line and is referred to as EcR PC 12 (gift from Aleksey Kazantsev).
Lipofectamine 2000 (Invitrogen) was used to stably transfect -galactosidase A-subunit in pIND
and a 97Q or a 23Q in pIND/Hygro into the EcR PC12 cells in two steps: 1. 3-galactosidase
A-subunit; 2. a 97Q or a 23Q. These steps generated A-a 97Q and A-a 23Q PC12 cell lines,
respectively.
Cell culture
A-a 97Q and A-a 23Q PC12 cells were grown in DME medium with 15% fetal bovine
serum, 2 mM penicillin-streptomycin, 2 mM L-glutamine at 37°C with 5% CO2. The pVgRXR,
pIND -galactosidase A-subunit, and pIND/Hygro a 97Q or a 23Q constructs were maintained
with 0.2 mg/ml Zeocin, 0.25 mg/ml Geneticin, and 0.1 mg/ml Hygromycin, respectively.
P-galactosidase activity assay
Either A-a polyQ cells were seeded at 50 x 104 cells/ml in 96-well format, induced with
5 gM Ponasterone A (AG Scientific) in DMSO, and then grown at 37°C for 24 hr. Each well
was then rinsed with PBS, and 10 gl of Modified RIPA added (150 mM NaCl, 50 mM Tris HCl
pH 7.4, 1 mM EDTA, 1% NP-40, 1% w/v Na-deoxycholate, stored at 4°C). 67 gl of a master
mix (5 gl 10x Cleavage Buffer, 0.135 gl 14.3 M P3-mercaptoethanol, 44.865 pl dH2O, 17 gl
4 mg/ml ONPG) from Invitrogen's 3-galactosidase Assay Kit was added to each well and
incubated at 37°C for 30-60 min. The addition of 125 gl of STOP Buffer (1 M Na2CO3 )
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stabilizes the colorimetric change of ONPG cleaved by 13-galactosidase, which was then read at
405 nm on a plate reader.
p-galactosidase activity is reported in nmoles of ONPG hydrolyzed. The absorbance at
405 nm can be converted to nmoles of ONPG hydrolyzed by the following formula:
nmoles of ONPG hydrolyzed = (OD a 405 nm) * (final vol =1.92x 105 n) = (OD4 05 .) * (42.667 nmole)
(4500 nl/nmole-cm) * (1 cm)
The data from the experimental wells was normalized by subtracting the amount of
f-galactosidase activity in un-induced wells.
Western Blots
Either A-a 97Q or A-a 23Q cells were seeded in 12-well plates at 50 x 104 cells/ml and
grown at 37°C for 24 hr. Proteins were extracted from cells with Lysis Buffer (50 mM Tris pH8,
100 mM NaCl, 5 mM MgCl2, 0.5% NP-40) and Complete Protease Inhibitors (Roche) at 2x, on
ice 30 min. Protein concentration was determined using Protein Assay and BSA standards
(Bio Rad). 10-15 gig of protein in SDS loading buffer with B-mercaptoethanol was heated at
80°C for 5 min, then loaded on an 8.5% acrylamide gel in a PROTEAN II system (Bio Rad).
Proteins were transferred to PVDF (Millipore) using 15% MeOH in transfer buffer (25 mM Tris,
190 mM glycine), at 80 V for 2 hr in 4°C.
PVDF blots were blocked in PBST with 0.5% milk for 1 hr. Actin (1:500, Sigma),
[-galactosidase (1:2000, MP Bio), or MAB2166 Htt (1:2000, Chemicon) antibodies were diluted
in PBST with 0.5% milk and incubated for 2 hr at room temperature or overnight at 4°C.
HRP-conjugated secondary antibodies were diluted in PBST with 0.5% milk and incubated with
blots for 30-45 min. Proteins were visualized with ECL Plus (Amersham Biosciences), and blots
exposed to MR film (Kodak).
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Figure 1: Beta-galactosidase activity as reporter assay for presence of Htt
A) The expression of neither the Beta-galactosidase alpha-fusion or delta-subunit is
sufficient for Beta-galactosidase activity. Co-expression of the alpha-fusion and delta-
subunit will re-constitute the Beta-galactosidase activity. The ideal compound is one
which specifically recognizes expanded Htt-97Q and promotes its degradation but does
not affect the level of normal Htt-23Q. This compound can be identified in the assay
because it will degrade the expanded Htt which is fused to the alpha-subunit. The
elimination of the alpha-subunit will eliminate Beta-galactosidase activity.
B) Inducible PC12 cell lines express the Beta-galactosidase delta-subunit and the Beta-
galactosidase alpha-subunit fused to the first 600 aa of Htt, containing either 23Q or
97Q. Both constructs are under the expression of the ecdysone inducible system.
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Figure 2: Stable EcR-delta PC12 cell lines identified.
EcR PC12 cell lines stably transfected with the Beta-galactosidase delta-subunit were
transiently transfected with a23Q, and subsequently induced with 5 uM PonA for 24 hr.
Beta-galactosidase enzymatic activity of each cell line was detected by the Invitrogen
Beta-galactosidasel Assay Kit and reported as nmoles of ONPG (B-galactosidase
substrate) hydrolyzed. Error bars indicate standard deviation. N=3.
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Figure 3: d-a97Q and d-a23Q PC12 cell lines are identified.
delta PC12 celllines stably transfected with either a970 (A) or a230 (B) were induced
with 5 uM PonA for 24 hr. Beta-galactosidase enzymatic activityof each celllinewas
detected by the Invitrogen Beta-galactosidase Assay Kit and reported as nmoles of
ONPG hydrolyzed. Error bars indicate standard deviation. N=12.
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(/gc~t~ 7/d/
some
d-a97Q #44 small difen 1.5 days 10% 9.2different
#46 small same >1day > 50% 18.5
#47 small same <1 day 10% 3.5
d-a23Q #9 smallish same 1 day 50% 9.2
#15 larger some 1 day > 50% 16.12
different
some more#17 larger different 1 day 25% 15.6different
#31 small same 1 day > 75% 92.9
some#44 small dife 1.5 day < 50% 20.9different
.,,,o - /
Table 1: Comparison of d-a97Q and d-a23Q cell lines.
The three d-a97Q (#45, #46, #47) and five d-a23Q (#9, #15, #17, #31, #44) cell lines
were examined on various parameters in order to choose the most ideal d-a97Q cell
line for HTS, and the best d-a23Q cell line to use as a counter screen for compound
specificity. Cell size and the amount of seemingly differentiated cells are comparative
measures. Doubling time was determined by a standard growth curve. The percent of
cells with Beta-galactosidase enzymatic activity was determined by inducing the cells
with 5 uM PonA for 24 hr and subsequently staining for Beta-galactosidase activity
using Invitrogen's Bgal Staining Kit. The total nmoles of ONPG that a population of
cells is capable of hydrolyzing was used as a measure of Beta-galactosidase enzymatic
activity, with Invitrogen's Beta-galactosidase Assay Kit. This was determined by
subtracting the nmoles of ONPG hydrolyzed in un-induced cells from the nmoles of
ONPG hydrolyzed in cells induced with 5 uM PonA for 24 hr.
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Figure 4: Induction with PonA directly correlates with Beta-galactosidase activity
and induced protein levels.
d-a23Q or d-a97Q cells were either untreated (0 uM) or induced with 1, 3, or 5 uM
Ponasterone A (PonA) for 24 hr. Cells were either assayed for Beta-galactosidase
activity using the Invitrogen's Beta-galactosidase Assay Kit (A) or lysed for Western blot
analysis (B, C). A) Higher concentrations of PonA result in more Beta-galactosidase
activity, as determined by nmoles of substrate hydrolyzed. Error bars indicate standard
deviation. N=5. B) Western blot analysis was used to detect the expressions of a23Q
or a97Q and actin using the MAB2166 Htt and Actin antibodies, respectively. C) The
detection of the Beta-galactosidase delta-subunit and Actin was achieved by the
Beta-galactosidase and Actin antibodies, respectively.
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Figure 5: Decrease in Beta-galactosidase activity correlates with reduction of
induced protein levels.
d-a97Q and d-a23Q cells were induced with 5 uM PonA. After 24 hr, the media of each
well was replaced either with media containing PonA (unwashed) or media without
inducer (washed). Cells were either assayed for Beta-galactosidase activity (A, B) or
lysed for Western blot analysis (C-F) at the following time points: 0, 24, 30, 36, 42, or
48 hr. d-a97Q data shown in A, C, E; d-a23Q data in B, D, F. A, B) The Beta-
galactosidase activity of continuously induced cells (closed) and of washed cells (open)
was determined using the Invitrogen Beta-galactosidase Assay Kit. Error bars indicate
standard deviation. C, D) Western blot analysis using MAB2166 Htt and Actin
antibodies to detect the a-Htt fusion expression and Actin, respectively. Upper bands
are inducible a-Htt fusion protein at full length, and lower bands are cleaved products of
a-Htt fusion protein. E, F) Western blot analysis using the Beta-galactosidase and Actin
antibodies.
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Figure 6: Z' Factor description
To accurately detect a shift in the mean of a population towards another population, the
two populations would ideally have a large distance between their means, and the
variance within each population would be minimal. In this assay, the two populations
are the negative control (0% Beta-galactosidase activity) and positive control (100%
Beta-galactosidase activity). The shift being detected is the change in Beta-
galactosidase activity from 1000/0with the addition of an active compound.
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CHAPTER III
IDENTIFICATION AND CHARACTERIZATION OF COMPOUNDS THAT
DECREASE EXPANDED HTT PROTEIN LEVELS
ABSTRACT
Huntington's disease (HD) is a progressively degenerative neurological disorder.
Individuals who inherit the IT15 gene with an expansion of the CAG repeat region inevitably
succumb to motor, psychological, and cognitive symptoms. I sought to identify chemical
compounds that specifically caused a decrease in intracellular levels of the disease-causing
expanded huntingtin (Htt) protein without reducing the levels of the protective normal Htt. In
this chapter, I describe the identification of compounds which meet these criteria, a proof of
principle for this approach. I further show that these compounds are effective in reducing
toxicity caused by expanded Htt in a cell based model system further validating this approach to
HD therapy. To carry out these studies I implemented a cell-based assay, using 3-galactosidase
activity as a reporter for Htt protein levels, as a secondary assay to characterize a group of 34
compounds initially identified in a High Throughput Screen format because they reduced levels
of expanded Htt fused to GFP. Of the 34 compounds characterized in the P3-galactosidase
A-a 97Q assay, dose response curves for 11 compounds verified their activity at 10 gM or less.
Counter-screening of these 11 compounds with A-a 23Q cells revealed that seven compounds
decrease -galactosidase activity only in A-a 97Q, and four compounds decrease P-galactosidase
activity in both cell lines. Immunofluorescence further demonstrates that two of the compounds
decrease levels of expanded but not normal Htt proteins in the cells. Finally, tests of toxicity on
HttQl0 3 PC-12 cells, which show specific toxicity following expression of an expanded Htt
protein, revealed a significant correlation with the results from the 3-galactosidase assay and the
identification of at least one compound which continued to meet the criteria for therapeutic
intervention in HD. These results support the feasibility of the development of an HD
therapeutic strategy based on small molecules which cause a specific reduction of intracellular
Htt expanded repeat protein levels and suggest a program of development for such molecules.
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INTRODUCTION
Huntington's disease (HD) is characterized by the progressive degeneration in motor,
psychological, and cognitive abilities [1, 2]. The genetic cause for this disease is an expansion of
the CAG repeats in the first exon of the IT15 gene, located on chromosome 4 [3, 4]. This
expansion in CAG repeats translates into an expanded poly-glutamine (polyQ) region in the
huntingtin (Htt) protein. Unaffected individuals have Htt with 6-35Q (normal Htt), while HD
patients have Htt with 40-100Q (expanded Htt). The variation in the polyQ expansion in patients
is correlated to age of onset, where patients with a larger polyQ region have a tendency to
present with symptoms earlier in life [5]. However, there is no correlation between the length of
the polyQ region and the rate of disease progression.
Htt expression is widespread throughout the body, with the highest levels of expression in
the central nervous system [6, 7]. Expanded Htt has been implicated in decreasing mitochondrial
activity [8-10], transcription [11-18], and protein degradation [19-23]. Loss of normal Htt can
further contribute to dysfunction in mitochondrial activity [9, 24], transcription [25], and protein
trafficking [9, 26 28]. Cell death has also been observed in HD. Brains from both symptomatic
and pre-symptomatic HD patients show a remarkable decrease in striatal and cortical neurons
[29-31]. Evidence of apoptosis in the brains is one mechanism of cell loss [32], while
excitotoxicity also contribute [33-35]. Nuclear inclusions containing Htt protein are observed in
surviving neurons in the brains of HD patients at autopsy. However, the pathological role of
such inclusions or their potentially beneficial role in cell survival remains a question of
significance [36].
Understanding of the dysfunctional cellular processes has lead to potential drug therapies,
in particular those targeting the mitochondria [37-44], transcription [18, 45-49], protein
degradation [50], and toxicity [51-60]. However, none of these drug treatments are effective
enough to be considered a viable HD treatment. One possible reason is that each of these drugs
target only one aspect of HD, leaving the possibility that symptoms arising from other
dysfunctions would persist.
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Alternative drugs have been targeted at aggregation, based on the proposal that the
toxicity caused by aggregated Htt is the cause of the cellular dysfunction. Support for this theory
comes from the presence of aggregated expanded Htt in the brains of HD patients [29, 30]. Pure
polyQ aggregates taken up by cells causes toxicity when the aggregates are targeted to the
nucleus [61]. Since caspase cleavage of Htt results in the elimination of the C-terminal nuclear
export signal [62], nuclear toxicity is a possible role for aggregated expanded Htt. In addition,
sequestered proteins such as chaperones, proteasome subunits, transcription regulating proteins,
and ubiquitin binding proteins are found in aggregates. The loss of function of these proteins can
lead to cellular dysfunction, and ultimately cell death. However, several potent aggregation
inhibitors have limited effects on survival of HD animal models [63-65], indicating that
inhibition of aggregation may be of limited effectiveness in treating HD.
Since expanded Htt, aggregated or not, has been implicated in many cellular
dysfunctions, a direct way to treat HD would be to eliminate the disease-causing expanded Htt
from cells. In order to evaluate the effect of removing expanded Htt after disease-onset, the
conditional mouse model HD94, where exon one of expanded Htt with 94Q is expressed in the
forebrain, was created [66]. When the expression of expanded Htt is eliminated after onset of
symptoms, the progression of motor dysfunction and neuronal loss is not only prevented but the
symptoms are actually reverted. If the expression is turned off at 10 months of age, the motor
dysfunction is completely rescued and aggregates are no longer visible [67]. However, if the
expression is turned off at 17 months of age, motor dysfunction is completely rescued without
any effect on aggregates [68]. The study of this mouse model indicates that removal of the
disease-causing expanded Htt is a viable treatment for the disease which can be beneficial at
multiple stages in disease progression.
The first attempt treating HD by eliminating expanded Htt was the use of RNAi
treatments in various HD mouse models, which improves survival and motor functions while
decreasing neuropathology [69-71]. These results with RNAi treatments are encouraging
because they show benefit even without complete elimination of expanded Htt. However, a
drawback to RNAi is that it can not be specific for expanded Htt because RNAi targets small
sections of mRNA sequence, which do not differ between expanded and normal Htt. Since
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normal Htt may serve a protective role, it is not ideal for an HD treatment to decrease the levels
of normal Htt.
An approach to the treatment of HD which, in principle, would be extremely attractive
would be to identify treatments that decrease the levels of expanded Htt while maintaining the
expression of normal Htt. The fact that expanded and normal Htt have different tertiary
structures [72] allows for the possibility that a chemical compound could have specificity to
expanded but not normal Htt. Here, a cell-based assay was implemented to identify compounds
that decrease the levels of expanded but not normal Htt proteins, making no assumptions as to
which cellular dysfunction causes the most harm to HD patients or which form of expanded Htt
is the most toxic to cells. This assay uses 3-galactosidase activity as a reporter for Htt protein
levels. PC12 cells expressing the 3-galactosidase delta-subunit (A), and either expanded (97Q)
or normal (23Q) Htt fused to the -galactosidase alpha-subunit (a) in an inducible fashion exhibit
f[-galactosidase activity. These A-a 97Q cells were used to screen compounds in a High
Throughput Screen format. Counter-screening with A-a 23Q cells and secondary assays
identified two compounds which decrease levels of expanded but not normal Htt proteins. These
data indicate that the A-a 97Q cells and A-a 23Q counter-screen are effective in identifying
compounds that selectively decrease expanded Htt protein levels serving as a proof of principle
for this approach to HD therapy.
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RESULTS
Validation of assay and identification of 11 effective compounds
A-a 97Q ]1PC12 cells were constructed as a cell-based assay to identify compounds that
decrease the level expanded Htt protein. The cell line is stably transfected with two constructs:
one encodes the B3eta-galactosidase (-galactosidase) delta-subunit (A), and the other encodes a
fusion between the first 600 aa of expanded Htt (with 97Q) and the P3-galactosidase alpha-subunit
(a). Thus, Htt protein levels are monitored by 3-galactosidase activity due to alpha-
complementation of 3-galactosidase A-subunit and a-subunit fused to Htt (a 97Q). Both the
f0-galactosidase A-subunit and a 97Q proteins are under the control of the inducible ecdysone
system and can be expressed upon the addition of the inducer Ponasterone A (PonA). A similar
cell line containing a normal length of the polyQ region, A-a 23Q, was also created to be used as
a counter-screen to identify compounds that specifically decrease the protein levels of expanded
but not normal Htt.
In order to validate A-a 97Q cells as capable of identifying compounds which decrease
fP-galactosidase activity by decreasing a 97Q protein levels, a collection of compounds
previously shown to decrease an N-terminal Htt fragment (Htt 1-17 aa) with 103Q fused to
EGFP was tested. Aleksey Kazantsev previously identified 114 compounds that decreased the
overall levels of EGFP (Fig 1A) [73]. Since these PC12 cells expressed only a small Htt
fragment with 103Q, any specific compound that affected the levels of EGFP was presumably
targeting the polyQ. However, some compounds might act non-specifically, for example by
disrupting transcription, ecdysone induction, or cell viability. Therefore, there was a distinct
likelihood that some compounds in this collection would be capable of decreasing
f3-galactosidase activity in A-a 97Q cells.
Kazantsev's lab tested these 114 compounds on the A-a 97Q cells in a High Throughput
Screen (HTS) format. Of the 114 compounds tested, 34 compounds showed less than 75%
f;-galactosidase activity as compared to induced cells without compound and were considered
hits. These 34 compounds were re-tested for validation by performing dose response tests on
A-a 97Q cells in a low-throughput manner. At 10 1 M, 17 compounds were found to have more
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than 101% P3-galactosidase activity, five compounds with 76-100% fP-galactosidase activity, and
one could not provide reproducible results (Fig 1B). These 23 compounds were considered false
positive compounds and were not further analyzed. The remaining 11 compounds showed linear
close response, and at 10 M had less than 75% P3-galactosidase activity. Specifically, one
compound had 0-.25% 3-galactosidase activity, five had 26-50% P3-galactosidase activity, and
five had 51-75% P-galactosidase activity.
Four classes of compounds identified by A-a 23Q counter-screen
The 11 compounds that caused 0-75% P3-galactosidase activity in A-at 97Q cells were then
tested in A-a 23Q cells by dose response curves to determine their specificity to expanded Htt.
Upon examination of the data, the compounds were categorized into four classes (Table 1).
Class I is composed of compounds that decrease P3-galactosidase activity in A-a 97Q cells, but
increase it in A-a 23Q cells as compared to induced cells without compound. The Class II
compound has complex effects on both cell lines. Class III compounds decrease 3-galactosidase
activity in A-a 97Q cells but have no effect on A-a 23Q cells. Finally, Class IV compounds
decrease P3-galactosidase activity in both cell lines. Classes I, II, and III are compounds that have
specificity to expanded Htt, and are described below. Class IV compounds are non-specific, and
will be described in a later section.
Characterization of seven specific acting compounds:
Seven specific acting compounds are grouped into Classes I I, and III
Compounds A7, A8, A9, and A24 were placed in Class I because between 1-10 M, none
caused the f3-galactosidase activity of A-a 97Q to rise above 125%, while the P3-galactosidase
activity of A-a 23Q does increase (Fig 2). These are the most promising compounds because if
f,-galactosidase activity is a true measure for either a 97Q or a 23Q proteins, then these
compounds have the ability to decrease the level of expanded Htt and increase the level of
normal Htt.
Compound A1 8 stands alone in Class II with its ability to dramatically increase
f;-galactosidase activity in both A-a 97Q and A-a 23Q cells at low concentrations (Fig 3).
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However, at higher concentrations, A18 does decrease 3-galactosidase activity in A-a 97Q cells
while still increasing the P3-galactosidase activity of A-a 23Q cells. Therefore, while there was
no specificity at low concentrations, the specificity at high concentrations has the potential of
making this a compound worth pursuing.
In Class III are compounds A25 and A31, which decreased the -galactosidase activity in
A-a 97Q but had no effect on A-a 23Q cells (Fig 4). These two compounds are interesting
because they have the potential of having selectivity for expanded Htt but not normal Htt. This
contrasts with earlier identified compounds that have effects on both expanded and normal Htt.
Effects of Class I, II, and III compounds on cell viability
Compounds that reduce cell viability would also cause a decrease in P3-galactosidase
activity in the assay. Therefore, the compounds were tested in a secondary assay for effects on
viability. Although these compounds had been previously tested for toxicity effects, each cell
line has different sensitivities to compounds. Therefore, they were tested for an effect on
viability (MTS mitochondrial activity assay) of A-a 97Q and A-a 23Q cell lines. Cells were
induced with PonA and either 5 or 10 pM compound for 24 hr, at which time the MTS solutions
were added. 100% MTS activity was defined as the activity of induced cells without compound.
A18 was the only compound that caused a decrease in viability in A-a 97Q cells (Fig 5). This
specific decrease in viability could explain the decrease in P3-galactosidase activity at 10 pM
since a well with fewer healthy or proliferating cells would have lower fP-galactosidase activity.
It is also interesting to note that no compound at 5 or 10 pM increased viability in
A-a 23Q cells. This indicates that the increase in fP-galactosidase activity observed in A-a 23Q
cells with Classes I (Fig 2) and II (Fig 3) compounds was not due to an increase in cell number.
Effects of Class I, II. and III compounds on P-galactosidase and Htt protein levels
Since 3-galactosidase activity level was being used as a reporter for Htt protein levels, it
was important to verify the assay results by measuring protein levels. Immunofluorescence was
used on A-a 97Q and A-a 23Q cell lines which had been induced and treated with 10 pM
compounds for 24 hr. Of all seven specifically acting compounds, only A9 and A24 were
capable of decreasing the level of a 97Q immunofluorescence (Figs 6 and 7). Comparison of
induced A-a 97Q or A-a 23Q cells with DMSO vs. compounds showed that none of the
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compounds had an effect on the cytoplasmic localization of Htt or P3-galactosidase proteins (data
not shown). In addition, none of the compounds had an effect on the level of P3-galactosidase
proteins in either cell line (data not shown).
Compound A9 at 10 M very dramatically decreased the level of a 97Q proteins as
compared to A-a 97Q cells which were treated with the drug vehicle DMSO (Fig 6A and B).
However, it had no effect on either a 23Q or 3-galactosidase A-subunit protein levels (Fig 6C
and D). This indicates that A9 very specifically causes a decrease in expanded Htt protein
levels, but does not affect normal Htt or other proteins induced from the same promoter.
Compound A24 at 10 gM showed a similar pattern in that it decreased a 97Q protein
levels (Fig 7A and B), although not as strongly as A9. Of additional interest, A24 actually
increased the level of a 23Q protein (Fig 7C and D). This change in protein levels directly
parallels the effect of the compound on P-galactosidase activity: it decreased P-galactosidase
activity in A-a 97Q and increased 3-galactosidase activity in A-a 23Q.
Compound A9 may decrease expanded Htt protein production
It was evident by looking at the expression of Htt proteins in A-a 97Q and A-a 23Q cells
with the addition of A9 or A24 that these compounds decreased the amount of a 97Q after 24 hr
of treatment. This decrease in a 97Q protein levels could be due to a decrease in the rate of
a 97Q protein production, an increase in the rate of a 97Q protein degradation, or a combination
of both.
To address this question, the f3-galactosidase activity in the first 12 hr of induction was
assessed in A-a 97Q and A-a 23Q cells. Cells were induced and treated with 10 gIM A9 or A24,
and f3-galactosidase activity was measured every 2 hr (Fig 8). Between 6-10 hr of expression,
both A-a 97Q and A-a 23Q cells with A9 had lower P3-galactosidase activity as compared to
induced cells without compound. However, at 12 hr the 3-galactosidase activity in A-a 97Q cells
was still lower, while A-a 23Q cells had caught-up to the control cells. This suggests that while
A9 may prevent the accumulation of a 97Q and a 23Q proteins at first, this effect is maintained
for a longer period of time with a 97Q but not a 23Q proteins.
In contrast, A24 had no effect on the increase of P3-galactosidase activity in the first 12 hr
of induction. This could suggest that the decrease in a 97Q protein observed at 24 hr with A24
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may be due to increased degradation of a 97Q. Similarly, the increase in a 23Q protein levels
observed could be due to reduced degradation of a 23Q.
Effect of Class I I and III compounds on HttQ l0 3 PC12 cell toxicity
In order to determine if the compounds had the ability to rescue cellular toxicity due to
expressed expanded Htt, they were tested in HttQ 103 PC12 cells. These cells have been shown to
have 50% toxicity upon induction of the expanded Htt [74]. Cells were induced with either 1, 5,
10, or 25 gM compound for 72 hr. The ability of the compounds to rescue toxicity was assessed
by the previously mentioned MTS assay.
All four compounds in Class I showed an ability to rescue toxicity in HttQ10 3 cells
(Fig 9A). More specifically, A7 only had partial rescue at 1 and 5 gM, and even caused
additional toxicity at 25 gM. A8, A9 and A24 had complete rescue, in a dose-dependent manner.
Since A9 and A24 were the only compounds that decreased a 97Q protein levels, HttQ103 cells
treated with 10 gM A9 or A24 were fixed and any changes in the GFP-tagged aggregates were
examined. Cells with DMSO control mainly had multiple aggregates per cell, infrequently had
either one or no aggregates, and never showed diffuse GFP (Fig 9B). Cells treated with A9
mainly had either one or no aggregates, some had diffuse GFP, and rarely were there multiple
aggregates per cell. Cells treated with A24 mainly had a single aggregate, occasionally had
multiple aggregates per cell, and sometimes had diffuse GFP. Cells which had one aggregate did
not show a diffuse GFP signal, indicating that A9 and A24 are most likely not affecting the
aggregation of Htt. The ability of the compounds to prevent multiple aggregates per cell is likely
due to an overall decrease in expanded Htt protein levels. The fact that nucleation of expanded
Htt requires a critical mass supports this theory since cells with low Htt protein levels would be
unable to form aggregates and thus have a diffuse expression pattern.
The only concentration of A18 that could rescue toxicity of HttQ l03 cells was 1 M
(Fig 9A). Perplexingly, it was at low concentrations that A1 8 increased the f3-galactosidase
activity in both A-a 97Q and A-a 23Q cells (Fig 3). Therefore, in this case, a compound that
increases the reporter for Htt protein levels can also rescue toxicity in a different cell line. Of the
two compounds in Class III, only A31 was able to rescue toxicity in HttQ 03 cells (Fig 9A).
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Characterization of four non-specific acting compounds:
Four compounds in Class IV non-specifically decrease D3-galactosidase activity
As mentioned before, the 11 compounds that caused 0-75% 3-galactosidase activity in
A-a 97Q cells were tested in A-a 23Q cells for their ability to specifically affect expanded Htt.
The seven compounds that were found to act specifically on A-a 97Q have already been
discussed. The four compounds that were found to decrease 1-galactosidase activity in both
A-a 97Q and A-a 23Q were A14, A15, A20, and A29 in Class IV (Fig 10). Each of these
compounds non-specifically decreased 3-galactosidase activity to 25-50% at 10 gM.
Effect of Class IV compounds on cell viability
The four non-specific acting compounds were tested for an effect on cellular viability of
A-a 97Q and A-a 23Q cell lines with the MTS assay, in order to identify compounds whose
effect on 0-galactosidase activity can be explained by a decrease in cell number. Cells were
induced PonA and either 5 or 10 gM compound for 24 hr, when the MTS solutions are added.
Compound A14 caused a decrease in viability in both cell lines (Fig 11). In addition to
this, it became apparent when looking at the wells that this compound caused a decrease in cell
number (data not shown). This decrease in cell number could easily explain the decrease in
03-galactosidase activity, therefore this compound was not further studied.
Effect of Class IV compounds on 1-galactosidase and Htt protein levels
In order to verify that the change in P3-galactosidase activity with compound correlated
with a change in Htt protein levels, immunofluorescence was used on A-a 97Q and A-a 23Q cell
lines. Cells were induced and treated with 10 gM compounds for 24 hr. Comparison of induced
cells with DMSO control vs compounds shows than none of the compound had an effect on Htt
or P-galactosidase protein cytoplasmic localization (data not shown). However, A1 5, A20 and
A29 were capable of decreasing the level of a 97Q and a 23Q proteins (Figs 12, 13 and 14).
Compounds A15 and A20 were similarly capable of decreasing both a 97Q and a 23Q
protein levels (Figs 12 and 13). However, these compounds also slightly decreased the
f-galactosidase A-subunit protein levels in A-a 23Q cells. While this may indicate that the
compounds were acting on all induced proteins, it is not necessarily the case since they did not
affect the levels of 3-galactosidase A-subunit protein levels in the A-a 97Q cell line. A29
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decreased the levels of a 97Q and a 23Q proteins (Fig 14). The protein level of P3-galactosidase
A-subunit was not affected, indicating that the decrease in Htt proteins was not a global effect on
induced proteins, but specific to Htt.
Effect of Class IV compounds on HttQ 03 PC12 cell toxicity
In order lo determine if the compounds had the ability to rescue cellular toxicity due to
expressed expanded Htt, they were tested in HttQ 103 PC12 cells, which have 50% toxicity upon
induction of the expanded Htt. Cells were induced with either 1, 5, 10, or 25 M compound for
72 hr. The ability of the compounds to rescue toxicity was assessed by assaying cellular viability
with the MTS assay. Only compound A1 5 could partially rescue HttQl03 toxicity (Fig 15).
Compound A14 had the same toxic effect on HttQl03 that it did on A-a 97Q and A-a 23Q cells,
validating the decision to not study it any further.
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DISCUSSION
In the attempts to find a treatment for HD, many cell models have been created to
recapitulate some aspect of the disease. In many cases, the disease phenotype that was being
targeted was toxicity [75, 76]. In other cases, inhibition of aggregation was the target [77].
While some of these assays have lead to the identification of interesting compounds, they each
target a very specific aspect of the disease. In the hopes of finding a compound which would
have the most dramatic effect on the disease, a cellular assay was designed to target the basic
cause of HD: expression of the expanded Htt protein.
In order to identify compounds that target expanded Htt, a cellular assay was created
which used -galactosidase activity as a reporter for the presence or absence of expanded Htt or
normal Htt. In these cells, A-a 97Q and A-a 23Q cell lines, the amount of a 97Q and a 23Q
protein levels has been shown to directly correlate with P-galactosidase activity. Thus
compounds that decrease P3-galactosidase activity in A-a 97Q cells might also decrease the levels
of expanded Htt.
To validate A-a 97Q cells as a useful drug-discovery assay, a collection of compounds
previously shown to decrease the protein levels of a small Htt fragment and 103Q was tested.
Since the A-a 97Q cell line contains the first 600 aa of Htt and all of the known caspase cleavage
sites [78], they have the ability for the Htt fragment to be cleaved down to a smaller fragment
which could be recognized by the compounds from the 103Q screen.
From the 114 compounds tested in an HTS-format, 34 were found to decrease
P3-galactosidase activity in A-a 97Q cells. Upon re-testing, 11 compounds were found to reliably
and consistently decrease [3-galactosidase activity. Of these, seven were found to act specifically
decrease P3-galactosidase activity in A-a 97Q cells but not A-a 23Q cells, and were
subcategorized into three classes defined by their dose response characteristics (Table 1).
Class I consisted of A7, A8, A9, and A24 which caused a decrease in P3-galactosidase activity of
A-a 97Q cells, but an increase in A-a 23Q cells. Interestingly, compounds A7, A8, and A9
belong to the same structural family of compounds. Class II consisted of only A1 8 which had
the ability to increase P3-galactosidase activity in both A-a 97Q and A-a 23Q at low
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concentrations, but decrease P-galactosidase activity at higher concentrations. While the trend of
effect of A1 8 was similar on both cell lines, there was a shift in the dose response curve, making
the decrease in P-galactosidase activity selective at 10 pM. In Class III were A25 and A31
which decreased P3-galactosidase activity in A-a 97Q cells but had no effect on A-a 23Q cells.
Finally, four compounds non-specifically decreased P3-galactosidase activity in both cell lines,
and were categorized into Class IV.
To understand more clearly the mode of action for each of these 11 compounds, three
additional assays were performed: cellular viability, Htt protein levels, and rescue of HttQl03
toxicity (Table 2). By examining how a compound performed across these experiments, two
distinct ways in which a compound may act to decrease f3-galactosidase activity in A-a 97Q cells
can be distinguished: decrease in Htt protein levels, and decrease in cell number.
Five compounds were found that decreased expanded Htt protein levels. Compounds A9
and A24 in Class I selectively decreased a 97Q protein levels, while compounds A15, A20, and
A29 in Class IV decreased both a 97Q and a 23Q protein levels. In each case, when a
compound had no effect on P-galactosidase activity in A-a 23Q cells, it also had no effect on
a 23Q protein levels. Similarly, those compounds which decreased 3-galactosidase activity in
A-a 23Q also decreased a 23Q protein levels. Since these compounds had no effect on cell
viability or 1-galactosidase delta protein levels, the likely mechanism for decreasing
P3-galactosidase activity is the decrease in a 97Q or a 23Q protein levels. However, the specific
mechanism underlying the decrease in protein levels remains to be elucidated.
Another mechanism for a decrease in ,3-galactosidase activity which can be readily
attributed to compounds is a decrease in cell number. Compound A1 8 in Class II caused a
decrease in cellular viability in A-a 97Q, while the non-specific compound A14 in Class IV
caused a decrease in both A-a 97Q and A-a 23Q cells. The toxic effects of these compounds at
the doses tested suggest that they should not be pursued further, except perhaps at still lower
doses.
The mechanism of action for the four remaining compounds (A7, A8, A25 and A31)
remains elusive. Since compounds A7, A8 in Class I and A31 in Class III have no detrimental
effect on cellular viability and they rescue HttQ103 toxicity to some degree, they remain
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compounds worth pursuing. Since their effect on P3-galactosidase activity is specific to the
expanded Htt cell line, they are compounds which in some way specifically recognize expanded
Htt but not normal Htt. Possible mechanisms include binding to expanded Htt to either change
its conformation or physically interfering with the two 3-galactosidase subunits to prevent alpha-
complementation. Relocalization of expanded Htt to a different cellular compartment to prevent
alpha-complementation has been ruled out by examining A-a 97Q and A-a 23Q cells.
Another potential mechanism for decreasing 3-galactosidase activity is decreasing the
3-galactosidase delta protein levels. A likely reason why no compounds were found with this
mechanism is that these compounds were already selected for their ability to decrease a small
fragment of Htt.
Of the compounds studied, A24 has the highest potential of being a worthy for drug
development. This compound has all the characteristics that would be ideal in treating the basic
cause of HD: decreasing disease-causing expanded Htt protein levels, increasing the protective
normal Htt protein levels, not affecting cellular proliferation, and functional rescue of a toxic cell
line. In the 34,000 compounds from the Chembridge library initially screened, this compound
was found to be the sole representative of its kind. However, these results serve as proof of
principle that compounds with the properties desired for HD therapy can be identified. To
identify compounds with similar properties to A24 two routes may be taken. First, medicinal
chemistry can be used to create new variations of the A24 structure which may have increased
potency for causing reduction in expanded Htt levels. Second, HTS screening of additional
chemical libraries may lead to the identification of compound scaffolds with similar modes of
action but increased potency. Success in either of these endeavors could bring the approach to
HD therapy outlined here significantly closer to practical implementation.
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MATERIALS AND METHODS
Cell culture
A-a 97Q and A-a 23Q PC12 cells were grown at 37°C with 5% CO2 in DME medium
supplemented with 15% fetal bovine serum, 2 mM penicillin-streptomycin, 2 mM L-glutamine.
The pVgRXR, pIND f3-galactosidase A-subunit, and pIND/Hygro a 97Q or a 23Q constructs
were maintained with 0.2 mg/ml Zeocin, 0.25 mg/ml Geneticin, and 0.1 mg/ml Hygromycin,
respectively.
HttQl0 3 PC12 cells were grown at 37°C with 10% CO2 in DME medium supplemented
with 25 mM HEPES, 5% calf serum, 5% horse serum, 2 mM penicillin-streptomycin, and 2 mM
L-glutamine. The plasmid was maintained with 0.5 mg/ml Geneticin.
p-galactosidase activity assay
A-a polyQ cells were seeded at 50 x 104 cells/ml in 96-well plate format induced with
3 gM Ponasterone A (AG Scientific) in DMSO, and then grown at 37°C for 24 hr. Each well
was then rinsed with PBS, and 10 l of modified RIPA was added (150 mM NaCl, 50 mM Tris
HCl pH 7.4, 1 mM EDTA, 1% NP-40, 1% w/v Na-deoxycholate, stored at 4°C). 67 jl of a
master mix (5 l 10Ox Cleavage Buffer, 0.135 il 14.3 M P3-mercaptoethanol, 44.865 il dH 20,
17 jl 4 mg/ml ONPG) from Invitrogen' s -galactosidase Assay Kit was added to each well and
incubated at 37°C for 30-60 min. The addition of 125 il of STOP Buffer (1 M Na2CO3 )
stabilizes the colorimetric change of ONPG cleaved by 3-galactosidase, which was then read at
405 nm on a plate reader.
,3-galactosidase activity is reported in nmoles of ONPG hydrolyzed. The absorbance at
405 nm can be converted to nmoles of ONPG hydrolyzed by the following formula:
nmoles of ONPG hydrolyzed = (OD (a 405 nm) * (final vol =1.92x 105 ni) = (OD4 05n) * (42.667 nmole)
(4500 nl/nmole-cm) * (1 cm)
The data from the experimental wells was normalized by subtracting the amount of
f-galactosidase activity in un-induced wells. To report percent of 3-galactosidase activity, 100%
P-galactosidase activity was defined as the activity of induced cells, while 0% activity was
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defined as the activity of un-induced cells. Subsequently, all experimental data is reported
relative to these two controls.
High Throughput Screen
A-a 97Q cells were seeded on 96-well plates at 10 x 104 cells per well in 200 gl of media
without selection drugs. In order to induce the expression of the 3-galactosidase A and a 97Q
constructs, PonA was added to a final concentration of 3 gM. Compounds from Chembridge
were dissolved in DMSO and screened at 5-10 gM concentrations, in triplicate. Eight wells were
used as positive controls and did not receive any compounds, and eight wells received un-
induced cells to determine 0-galactosidase background activity level. The screen was performed
at MIND CAGn by Deb Russel and Steven Altman, supervised by Aleksey Kazantsev.
MTS assay
A-a polyQ cells were seeded at 10 x 10 4 cells/96-well or HttQl0 3 PC12 cells at 2 x 10 4
cells/96-well and then grown for either 24 hr or 72 hr, respectively. 40 gl of MTS/PMS
(Promega) was added to each well and incubated for 2-4 hr. The colorimetric change of MTS
converted was read at 490 nm on a plate reader. The data from the experimental wells was
normalized by subtracting the reading from medium-only wells.
Immunofluorescence
A-a polyQ cells were seeded at 50 x 104 cells/ml in chamber slides and grown for 24 hr.
The cells were then fixed with 4% paraformaldehyde and blocked with 10% goat serum in PBS
for 1 hr. MAB2166 Htt (1:500 Chemicon) or P3-galactosidase (1:2000 MP Bio) antibodies and
secondary antibodies (Alexa-488 and -594 1:200) were diluted in 10% goat serum and 0.2%
Tween in PBS and incubated for 1 hr.
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Figure 1: Verification of the compounds from HTS
A) Distribution of hits from 103Q HT~ B) Distribution of hits from d-a97Q low-through
put validation of 34 hits from d-a97Q HTS. d-a97Q cells were induced with 3 uM PonA
and 10 uM compound for 24 hr. Beta-galactosidase activity was determined using
Invitrogen's Beta-galactosidase Assay Kit. 1000/0Beta-galactosidase activity is defined
as the activity of induced cells without compound, and the Beta-galactosidase activity of
un-induced cells is subtracted from all data. Compounds were categorized into five
groups: 0-25%, 26-50%, 51-75%, 76-100%, or >100% Beta-galactosidase activity. Of
34 compounds, 11 were found to reproducibly cause less than 75% Beta-galactosidase
activity in d-a97Q cells and were further analyzed.
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Compounds
Relative Beta-galactosidase activity
d-a97Q d-a23Q
I
II
III
IV
A7, A8, A9, A24
A18
A25,A31
A14, A15, A20, A29
down
complex
down
down
up
complex
same
down
Table 1: Counter-screen d-a23Q categorizes 11 compounds into four classes
The 11 compounds verified to decrease Beta-galactosidase signal in d-a97Q were
counter-screened in d-a23Q cells. Relative Beta-galactosidase activity is compared to
induced cells without compound. Compounds in Class I raise the Beta-galactosidase
signal in d-a23Q cells. The compound in Class II has complex effects in both cell lines.
Compounds in Class III have no effect on Beta-galactosidase activity in d-a23Q cells.
Compounds in Class IV decrease Beta-galactosidase activity in both cell lines.
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Class I
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Figure 2: Class I compounds decrease Beta-galactosidase activity in d-a97Q but
not d-a23Q
d-a97Q (triangles) and d-a23Q (squares) cells were induced with 3 uM PonA and upto
10 uM compound for 24 hr. Beta-galactosidase activity was determined using
Invitrogen's Beta-galactosidase Assay Kit. 100% Beta-galactosidase activity is defined
as the activity of induced cells without compound, and the Beta-galactosidase activity of
un-induced cells is subtracted from all data. In each of these four compounds, Beta-
galactosidase activity rises above 125% in d-a23Q but not in d-a97Q cells. Y-axis
indicates relative Beta-galactosidase enzymatic activity. X-axis indicates uM
compound. Error bars indicate standard deviation. Asterisk indicates P<0.005 when
comparing vs. 0 uM. N=5 for data points in the first column of graphs, and N=3 for
data points in the second column of graphs.
74
175%
150%
125%
100%
75%
50%
25%
no/.
-&d-a97Q
-_d-a23Q
*
L ~*
_ _ o-M~~t
I 
0 2 4 6 8 10
*
*
* *175%
150%
125%
100%
75%
50%
25%
0%
* *
* f T :'_s;
0 2 4 6 8 10
175%
150%
125%
100%
75%
50%
25%
no/n
A24
rciiiuiiiiN
10
175%
150%
125%
100%
75% --------
50%
25%
0%
0 2 4 6 8
- - - - - - - - - - - -
Vl -m
m, _% _ _ .
V /u
0Y3
------------
Class II -*d-a97Q
-wd-a23Q
CI
u~N ~ ~r
Figure 3: A18 decreases Beta-galactosidase activity in d-a97Q but not d-a23Q at
high dosage
d-a97Q (diamonds) and d-a23Q (squares) cells were induced with 3 uM PonA and
either 1, 2, 5, 8, or 10 uM compound for 24 hr. Beta-galactosidase activity was
determined using Invitrogen's Beta-galactosidase Assay Kit. 100% Beta-galactosidase
activity is defined as the activity of induced cells without compound, and the Beta-
galactosidase activity of un-induced cells is subtracted from all data. With this
compound, Beta-galactosidase activity rises above 125% in both d-a97Q and d-a23Q
cells. Y-axis indicates relative Beta-galactosidase enzymatic activity. X-axis indicates
pM compound. Error bars indicate standard deviation. Asterisk indicates P<0.005
when comparing vs. 0 uM. N=5 for data points in the first column of graphs, and N=3
for data points in the second column of graphs.
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Figure 4: A25 and A31 decrease Beta-galactosidase activity in d-a97Q but not
d-a23Q
d-a97Q (diamonds) and d-a23Q (squares) cells were induced with 3 uM PonA and
either 1, 2, 5, 8, or 10 uM compound for 24 hr. Beta-galactosidase activity was
determined using Invitrogen's Beta-galactosidase Assay Kit. 100% Beta-galactosidase
activity is defined as the activity of induced cells without compound, and the Beta-
galactosidase activity of un-induced cells is subtracted from all data. With these two
compounds, Beta-galactosidase activity does not rise above 125% in either d-a97Q or
d-a23Q cells. Y-axis indicates relative Beta-galactosidase enzymatic activity. X-axis
indicates puM compound. Error bars indicate standard deviation Asterisk indicates
P<0.005 when comparing vs. OuM. N=5 for data points in the first column of graphs,
and N=3 for data points in the second column of graphs.
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Figure 5: Only A18 decreases cellular viability
d-a97Q (A) and d-a23Q (B) cells were induced with 3uM PonA and either 5 or 10 uM
compound for 24 hr. Cell viability was determined using Promega's MTS Assay Kit.
100% MTS activity is defined as the activity of induced cells without compound (0 uM).
V-axis indicates relative MTS activity. Error bars indicate standard deviation. Asterisks
indicate P<O.005 when compared to 0 uM. N=6.
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Figure 6: A9 decreases a97Q but not a23Q or Beta-galactosidase delta-subunit
protein levels.
d-a97Q (A-B) and d-a23Q (C-D) cells were induced with 3 uM PonA and compound for
24 hr. DAPI (first column) stain was used to visual the nuclei, Alexa-594 for the Beta-
galactosidase antibody (middle column), and Alexa-488 for the MAB2166 Htt antibody
(last column).
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Figure 7: A24 decreases a97Q but increases a23Q protein levels.
d-a97Q (A-B) and d-a23Q (C-D) cells were induced with 3 uM PonA and compound for
24 hr. OAPI (first column) stain was used to visual the nuclei, Alexa-594 for the Beta-
galactosidase antibody (middle column), and Alexa-488 for the MAB2166 Htt antibody
(last column).
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Figure 8: A9 lowers the rate of increase of Beta-galactosidase activity
d-a97Q (A) and d-a23Q (B) cells were induced with 3 uM PonA and either 10 uM of
A24 or A9. Beta-galactosidase activity was assayed every 2 hr, beginning at 4 hr after
induction and ending at 12 hr after induction. Error bars indicate standard deviation.
Asterisks indicate P<0.005 when compared to induced cells without compound. N=4.
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Figure 9: Almost all Class I and III compounds rescue toxicity of HttQ103 PC12
cells, and compounds A9 and A24 alter the presentation of GFP aggregates
HttQ103 PC12 cells were induced in the presence of either 1, 5, 10, 15, or 25 uM
compound for 72hr. A) 100% MTS activity is defined as the activity of un-induced cells
(white bars). A compound is determined to rescue toxicity when the MTS activity is
significantly higher than that of induced cells with DMSO control (0 uM, hatched bars),
emphasized with the dashed line. Y-axis indicates relative MTS activity. Error bars
indicate standard deviation. Asterisks indicate P<0.005 when compared to induced
cells without compound. N=6 for each data point, except the 25 uM data points where
N=3. B) Comparison of induced cells at 72 hr with DMSO control or A9 or A24 at 10
uM. DAPI was used to stain nuclei, and green indicates the expression of the HttQ1 03_
GFP construct.
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Figure 10: A14, A15, A20, and A29 decease Beta-galactosidase activity in both
d-a97Q and d-a23Q.
d-a97Q (triangles) and d-a23Q (squares) cells were induced with 3 uM PonA and upto
10 uM compound for 24 hr. Beta-galactosidase activity was determined using
Invitrogen's Beta-galactosidase Assay Kit. 100% Beta-galactosidase activity is defined
as the activity of induced cells without compound, and the Beta-galactosidase activity of
un-induced cells is subtracted from all data. Y-axis indicates relative Beta-
galactosidase enzymatic activity. X-axis indicates uM compound. Error bars indicate
standard deviation. Asterisks indicate P<0.005 when compared to induced cells without
compound. N=5.
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Figure 11: A14 decreases cellular viability
d-a97Q (A) and d-a23Q (8) cells were induced with 3 uM PonA and either 5 or 10 uMcompound for 24 hr. Cellular viabilitywas determined using the MTS Assay Kit. 100%
MTS activityis defined as the activityof induced cells without compound. Y-axis
indicates relative MTS activity. Error bars indicate standard deviation. Asterisks
indicate P<0.005 when compared to induced cells without compound. N=6 for A 14 and
A 15, N=3 for A20 and A29.
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Figure 12: A15 decreases a97Q and a23Q protein levels
d-a97Q (A-B) and d-a23Q (C-D) cells were induced with 3 uM PonA and compound for
24 hr. DAPI (first column) stain was used to visual the nuclei, Alexa-594 for the Beta-
galactosidase antibody (middle column), and Alexa-488 for the MAB2166 Htt antibody
(last column).
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Figure 13: A20 decreases a97Q and a23Q protein levels
d-a97Q (A-B) and d-a23Q (C-D) cells were induced with 3 uM PonA and compound for
24 hr. OAPI (first column) stain was used to visual the nuclei, Alexa-594 for the Beta-
galactosidase antibody (middle column), and Alexa-488 for the MAB2166 Htt antibody
(last column).
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Figure 14: A29 decreases a97Q and a23Q protein levels
d-a97Q (A-B) and d-a23Q (C-D) cells were induced with 3 uM PonA and compound for
24 hr. OAPI (first column) stain was used to visual the nuclei, Alexa-594 for the Beta-
galactosidase antibody (middle column), and Alexa-488 for the MAB2166 Htt antibody
(last column).
86
MTS on Htt Q103
125%
100%
75%
50%
25%
0%
LA14
Class
A15
IV
A20 A29~
r •o unfnduced
I fia OuM
'_1uM
i_5uM
_10uM
I_ 25uM
Figure 15: A15 rescues toxicity of HUQ103 PC12 cells
HttQ103 PC12 cells were induced in the presence of either 1, 5, 10, or 25 uM
compound for 72 hr. 1000/0 MTS activity is defined as the activity of un-induced cells
(white bars). A compound is determined to rescue toxicity when the MTS activity is
significantly higher than that of induced cells with DMSO control (0 uM, hatched bars),
emphasized with the dashed line. Y-axis indicates relative MTS activity. Error bars
indicate standard deviation. Asterisks indicate P<0.01 when compared to induced cells
without compound. N=6, except A 14 where N=6.
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Table 2: Summary of the effects of each compound on assays tested
Table indicates summary of effect of each of the compounds on the assays tested:
cellular viability of d-a97Q or d-a23Q, protein levels of a97Q or a23Q, and rescue of
HttQ 1 03 toxicity. Results are relative to induced cells without compound, positive
controls. The compounds are organized by Classes , II, III, and IV. A9 and A24 have
the most ideal characteristics across the assays, namely no affect on cellular viability, a
decrease in a97Q but not a23Q protein levels, and rescue of Htt-Q 1 0 3 PC12 toxicity.
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CHAPTER IV
FUTURE DIRECTIONS EXTENDING THE WORK DESCRIBED HERE
ABSTRACT
A number of lines of investigation should be pursued to extend the work described here
towards the ultimate goal of identifying an effective therapeutic intervention for HD. It would
clearly be of significance to expand screening of chemical libraries in the hope of identifying
compounds with higher levels of activity and alternative structures for further development
through medicinal chemistry. An important line of investigation which should be pursued will
be to establish the mechanistic basis by which identified compounds cause their effect on Htt
protein levels. It would also be valuable to expand the range of cell and animal models in which
compounds are characterized to develop a better understanding of the range of physiological
conditions under which a compound will remain active in specifically decreasing endogenous
expanded Htt protein levels. New cell lines can also be developed for more efficient screening
and characterization of compounds. Finally, detailed analysis through medicinal chemistry to
establish structure activity relationships for specific compound families would be an important
part of this effort. In the course of this discussion some preliminary data that support the
feasibility of particular lines of investigation is presented.
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FUTURE DIRECTIONS
A cell-based assay was designed and constructed in order to identify compounds that
specifically decrease expanded Htt but not normal Htt protein levels (Chapter II).
3-galactosidase activity in these cells, A-a 97Q and A-a 23Q PC 12 cells, was used as a reporter
for the presence of expanded or normal Htt proteins. A collection of 114 compounds were
screened in A-a 97Q cells in an HTS format successfully validating the assay (Chapter III). Of
34 compounds that emerged from the screen, 11 were confirmed by dose response curves in
A-a 97Q cells. These 11 validated compounds were then counter screened in A-a 23Q cells to
determine their specificity to expanded Htt. The compounds were further characterized by
assessing their ability to decrease protein levels and functionally rescue the toxicity of another
HD cell model. These data showed that the assay system described here utilizing A-a 97Q and
A-a 23Q cells can be successfully used to identify compounds which specifically decrease
expanded Htt protein levels.
In this chapter, I will discuss the future directions which I believe should follow these
studies. In the course of this discussion I will present some preliminary data that support the
feasibility of particular lines of investigation.
Direct use of the A-a 97Q and A-a 23Q cells as a primary HTS
It would clearly be desirable to identify additional compounds which have chemical and
functional properties that are appropriate as a starting point for therapeutic intervention in HD.
The compounds screened in Chapter III were pre-selected in that they were previously shown to
decrease the levels of a smaller Htt fragment with 103Q. The use of A-a 97Q cells as a primary
screening system would be preferable vs. a primary screen utilizing a smaller Htt fragment
because the target polypeptide in the A-a 97Q screening system would be more likely to closely
resemble the conformation of native full length Htt.
In order to assess the performance of A-a 97Q cells in a full-scale HTS, these cells were
used to screen a 5,000 compound collection (from Maybridge) in collaboration with Aleksey
Kazantsev and his laboratory. Thirteen compounds were found to decrease 3-galactosidase
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activity to below 75% of induced cells without compound. This hit rate of 0.26% was similar to
other screens; for example, the 0.36% hit rate in the Htt-103Q PC 12 cell line used to screen
36,000 compounds [1].
Dose response curves on A-a 97Q cells were used to verify the HTS results. At 10 gM,
one compound had more than 75% 3-galactosidase activity (Fig 1). This was considered a false
positive and not further analyzed. The remaining 12 compounds showed linear dose responses,
and at 10 gM had less than 75% 3-galactosidase activity. Specifically, three had 0-25%
P3-galactosidase activity, three had 26-50% 3-galactosidase activity, and six had 51-75%
3-galactosidase activity.
The 12 compounds that caused 0-75% 3-galactosidase activity in A-a 97Q cells were then
tested in A-a 23Q cells for their ability to specifically affect expanded Htt. Three compounds did
not decrease the P-galactosidase activity of A-a 23Q cells below 75% and were considered
compounds with specificity to expanded Htt (Fig 2). The three specifically acting compounds
(M4, M5, and M6) each caused no change in 03-galactosidase activity in A-23Q cells, and thus
were categorized into Class III of compounds previously described in Chapter III. While
compounds M4 and M5 caused the most striking difference between 3-galactosidase activities of
A-a 97Q and A-a 23Q cells at 10 gM, compound M6 had the best effect at 1 xM.
Of the 12 compounds which caused 0-75% P3-galactosidase activity in A-a 97Q cells, nine
were found to also decrease 3-galactosidase activity in A-a 23Q cells and were categorized into
Class IV of compounds previously described in Chapter III (data not shown). Of these, three had
0-25% 3-galactosidase activity, four had 26-50% P3-galactosidase activity, and one had 51-75%
p-galactosidase activity in both cell lines. One compound caused a greater decrease in
3-galactosidase activity in A-a 23Q cells than in A-a 97Q cells.
Further experiments should be performed to fully characterize the 12 compounds. The
viability of cells with addition of compound should be determined with the mitochondrial
activity MTS assay to identify those compounds that decrease 3-galactosidase activity by
decreasing cell number (similar to Chapter III Figs 5 and 11). Immunofluorescence on these
cells should be performed to identify what effects these compounds have on a 97Q, a 23Q, or
3-galactosidase A-subunit protein levels or cellular localization (similar to Chapter III Figs 6, 7,
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12-14). Finally, these compounds should be tested on HttQ10 3 PC 12 cells to check their ability to
functionally rescue toxicity (similar to Chapter III Figs 9 and 15). The results of these
experiments will allow the characterization of compounds that cause a decrease in a 97Q protein
levels and can functionally rescue toxicity, and are therefore of potential interest for further
development. The effective use of the A-a 97Q cell based assay in an HTS format suggests that
the use of this assay for the screening of additional chemical libraries is likely to be productive.
Mechanistic analysis of decrease in expanded Htt protein level with compounds
Chapter III described a series of experiments that were performed to help determine the
mode of action of seven compounds found to decrease P3-galactosidase activity specifically in
A-a 97Q cells, and four compounds found to decrease 3-galactosidase activity non-specifically in
A-a 97Q and A-a 23Q cells. The analysis of these experiments showed that five compounds
caused a decrease in Htt protein levels, two compounds specifically in A-a 97Q cells and three in
A-ct 97Q and A-a 23Q cells. The mechanistic basis for the activity of each compound is an
important question which should be explored further.
Decrease protein production vs. increased protein degradation
A question of interest which can be answered with greater clarity is the extent to which a
compound acts at the time of synthesis of the polypeptide chain to influence its rate of
production vs. the potential effect on the stability of a polypeptide chain increasing its rate of
degradation. One experimental protocol which can give insight into this question would be to
examine the rate of decrease of P3-galactosidase activity and immunofluorescence in A-a 97Q and
A-a 23Q cells with the addition of compound, a wash-out experiment. Figure 3 shows
preliminary data with 10 laM A25 where A-a 97Q and A-a 23Q cells were induced for 24 hr.
The media from each well was removed and replaced with either media without inducer, or
media without inducer but with A25. In this case, A25 had no effect on the rate of decrease of
fl-galactosidase activity upon removal of inducer. A complementary experiment which can
provide additional information on the question of a compound's effect the production vs.
degradation of expanded Htt protein is an induction time course (similar to Chapter III Fig 8).
This could be followed, in principle, by a pulse labeling experiment. In this protocol, protein
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production is quantified by incorporation of a labeled amino acid such as 35S Methionine. By
running protein samples taken over a time course on an acrylamide gel, a change in the
instantaneous rate of production of a 97Q in the presence of a compound can be determined.
Taken together these experiments can distinguish effects of a compound on the instantaneous
rate of production of a 97Q and the subsequent rate of degradation of a 97Q.
Decrease in the instantaneous rate of synthesis of expanded Htt
The identification of a mechanism of action for compounds which reduce the
instantaneous rate of synthesis of a 97Q will be quite challenging. It is worth noting, however,
that characterization of nascent polypeptide chain interactions inside the ribosome during
synthesis provide strong evidence for distinctive chaperone activity within the ribosome tunnel
as a nascent chain is undergoing elongation [2]. The events which occur during the folding and
processing of nascent chains could be the sites of specificity for the action of compounds which
impact on the instantaneous rate of synthesis of a 97Q. Characterization of a 97Q and a 23Q
behavior in systems designed to recapitulate these effects in vitro could lead to a mechanistic
understanding of the basis of action of compounds which affect these processes.
Increase in the rate of degradation of expanded Htt
Several experiments could elucidate what aspects of degradation could be affected by a
compound which causes an increased degradation rate for a 97Q. One mechanism for an
increase in degradation could be proteasome targeting, which has been implicated in HD [3]. To
address this possibility, a variation on the wash-experiment can be performed. Here, A-a 97Q
and A-a 23Q cells would be induced for 24 hr at which time the media is replaced with new
media containing either a proteasome inhibitor and compound, or a proteasome inhibitor alone.
If the P-galactosidase activity in cells with proteasome inhibitor and compound decreases as
compared to cells with proteasome inhibitor but no compound, then the pathway of degradation
is proteasome-independent.
Chaperones play a role in the rate of degradation and have also been implicated in HD
[4]. If a compound affects the effectiveness of a chaperone that participates in the folding of
a 97Q, this could result in a higher percentage of misfolded a 97Q proteins which, would then be
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targeted for degradation. In vitro assays of chaperone activity could be useful in determining the
impact of compounds on these pathways.
Of interest in this regard is a recent report showing that 17-AAG, an analog of
geldanamycin, both hsp-90 inhibitors, specifically decreases protein levels of the Androgen
receptor with expanded polyQ but not normal polyQ, and in doing so ameliorates an SBMA
mouse model of its disease symptoms [5]. It was of interest to determine if this compound
would also have specificity to expanded Htt, since this is precisely the type of compound which
A-a 97Q and A-a 23Q cells were designed to identify in an HTS. However, 17-AAG was
unavailable at the time so geldanamycin was tested instead. Interestingly, geldanamycin caused
a decrease in P-galactosidase activity in both A-a 97Q and A-a 23Q cells, even at very low
concentrations (Fig 4). Analysis of viability by the MTS assay will determine if geldanamycin
decreases 3-galactosidase activity by decreasing cell number (similar to Chapter III Figs 5 and
11), a possibility since it is known to have some toxicity. If this result is negative,
immunofluorescence on cells would determine if geldanamycin decreases both a 97Q and a 23Q
protein levels (similar to Chapter III Figs 6, 7, 12-14). If geldanamycin does indeed decrease
both a 97Q and a 23Q protein levels, it may suggest that 17-AAG does not recognize a protein
by its expanded polyQ region alone, but perhaps by the polyQ region in context of the protein.
This would explain why 17-AAG can have specificity to expanded AR but geldanamycin would
recognize both expanded and normal Htt. In addition, the effects of 17-AAG would ideally be
tested on A-a 97Q and A-a 23Q cells in order to make this conclusion.
Further validation of compounds in additional cell-based and animal assay systems
To further the overall goals of identifying an effective therapeutic intervention for HD, it
would be desirable to continue validating compounds on other HD assay systems. One such
system could be a novel cell-based assay designed to determine the range of polyQ lengths
recognized by the compound. It would also be beneficial to show that the compound decreases
endogenous full length expanded Htt protein levels in other HD model cells. Finally, testing the
compounds on HD animal models for rescue of symptoms is an essential step before proceeding
to human clinical trials.
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Decrease -galactosidase activity in A-a (intermediate polyQ) PC 12 cells
Testing the effect of compounds on A-a 97Q and A-a 23Q cells allows the determination
of the specificity of a compound for expanded Htt. Creating new cell lines with intermediate
lengths of polyQ would help determine at what polyglutamine length the compounds are
specific. Compounds tested only in cell lines with very high polyQ lengths may not be effective
for treating HD because the majority of HD patients have 40-50 glutamines [6]. It would
therefore be import to utilize cell lines expressing Htt with polyQ lengths similar to those seen in
most HD patients to validate compounds identified in screens based on longer poly Q lengths.
Decrease full length expanded Htt protein levels in cell models
It would be beneficial to examine the effects of the compounds on cell lines that express
both full length expanded and normal Htt in an endogenous manner. One such cells line is
StHdh Q 1 /Q7 which is a straital cell line from a knock-in transgenic mouse where 111Q have
been knocked-in to one of the Htt alleles [7]. Another useful cell line would be human
lymphoblasts cells from HD patients.
Preliminary work has been done to optimize the analysis of Htt protein levels from
StHdh QI 1 /Q7 (Fig 5A) and human lymphoblast cells (Fig 5B, C). The Western blots for the
fll length Htt proteins show that the expanded and normal Htt proteins can be separated and
identified (Fig 5A and B). This allows for the possibility of identifying a compound which
decreases the expanded Htt protein levels in any of these cells. In addition, a Western blot for a
collection of human lymphoblasts shows that endogenous Htt with different lengths of polyQ can
be cleaved into different length Htt fragments (Fig 5C). This is helpful because these Western
blots could also identify compounds which may not have any effect on full length but would
decrease Htt fragments levels.
While Western blots have the ability to identify compounds which affect the levels of full
length or fragment Htt proteins, they are not very effective in determining if there is a change in
fiull length Htt which exist in aggregates. In order to address this, filter trap assays could be
performed. In this experiment, protein extracts are run through a membrane that allows soluble
proteins to pass through but aggregated proteins remain trapped. The amount of protein on the
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membrane can then be quantified to determine if the addition of compound to cells affects the
levels of aggregated protein.
Rescue of symptoms and premature death in animal models
Using cell models is a good start in identifying compounds which could be drug
candidates. To continue with more complex systems, certain animal models can be tested. For
example, the compounds can be tested for rescue of toxicity in an HD yeast model [8, 9].
Similarly, they can be tested for rescue of toxicity in an HD Drosophila model [ 10, 11 ]. If a
compound succeeds in rescuing these animals, then it can be tested in an HD mouse model for
rescue of behavior, neuropathology, and death [12].
Identification of compounds of higher activity
While some compounds identified thus far may be potential candidates for further
development, it would clearly be desirable to identify compounds which show desirable activity
at a lower concentration range. The screening of additional libraries is clearly one route to such
compounds. The exploration of novel compounds structurally related to ones found to be active
would be of significance. In addition, structure activity relationships may provide insight into
the molecular target of each compound series. Two complementary routes towards the
acquisition of structurally related compounds for each active compound are available.
Pre-existing compound libraries
The compounds tested thus far have been acquired from sources which have already
synthesized many additional compounds which include structurally related compounds for each
compound tested. An initial strategy which may be taken is therefore to acquire a series of such
structurally related compounds and test them in the assays described here. A preliminary picture
of structure activity relationships may emerge from such studies.
Medicinal chemistry
Despite the availability of many such compounds from suppliers, as a study of this type
proceeds, it will likely become necessary to synthesize de novo a series of compounds which test
specific hypotheses or are likely to have higher biological activity. The further development of a
compound series which shows good activity in cell-based assays may also include attention to
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structural features of candidate molecules which improve bioavailability, serum half-life, and
blood brain barrier penetration, while retaining the original specificity for reduction in levels of
expanded Htt protein.
Final thoughts
The original motivation for the work described in this thesis was to contribute to the
development of a therapeutic intervention for HD. Upon learning about all the various cellular
dysfunctions that contribute to the disease symptoms, I thought targeting only one of these
pathways would not necessarily have any significant effect on the HD patient. Therefore, I
believed that the optimal way to treat HD was to target all of the cellular dysfunctions, and the
simplest way to accomplish this would be to use one drug that targets the common underlying
cause for all of the dysfunctions. I rationalized that people who do not express the expanded Htt
protein do not exhibit HD symptoms, therefore if I could identify a compound that eliminates
this disease-causing protein then it would be the optimal way to treat the disease. It is my hope
that the results and discussion in this thesis have provided an incremental contribution towards
the development o)f a therapy for HD.
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MATERIALS AND METHODS
Cell culture
A-a 97Q and A-a 23Q PC12 cells were grown at 37°C with 5% CO2 in DME medium
supplemented with 15% fetal bovine serum, 2 mM penicillin-streptomycin, and 2 mM
L-glutamine. The pVgRXR, pIND 3-galactosidase A-subunit, and pIND/Hygro a 97Q or a 23Q
constructs were maintained with 0.2 mg/ml Zeocin, 0.25 mg/ml Geneticin, and 0.1 mg/ml
Hygromycin, respectively.
Lymphoblast cells were grown at 37°C with 5% CO2 in RPMI medium supplemented
with 15% fetal bovine serum and 2 mM penicillin-streptomycin.
StHdh (Q 11 /Q7) cells were grown 33°C with 5% CO2 in DME medium supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, and 200 ug/ml Geneticin.
P-galactosidase activity assay
A-a polyQ cells were seeded at 50 x 104 cells/ml in 96-well plate format induced with
3 gM Ponasterone A (AG Scientific) in DMSO, and then grown at 37°C for 24 hr. Each well
was then rinsed with PBS, and 10 jtl of modified RIPA was added (150 mM NaCl, 50 mM Tris
HCI pH 7.4, 1 mM EDTA, 1% NP-40, 1% w/v Na-deoxycholate, stored at 4°C). 67 pil of a
master mix (5 gl 10x Cleavage Buffer, 0.135 gl 14.3 M P3-mercaptoethanol, 44.865 gl dH2O,
17 pgl 4 mg/ml ONPG) from Invitrogen's 3-galactosidase Assay Kit was added to each well and
incubated at 37°C for 30-60 min. The addition of 125 gl of STOP Buffer (1 M Na2CO3)
stabilizes the colorimetric change of ONPG cleaved by -galactosidase, which was then read at
405 nm on a plate reader.
P3-galactosidase activity is reported in nmoles of ONPG hydrolyzed. The absorbance at
405 nm can be converted to nmoles of ONPG hydrolyzed by the following formula:
nmoles of ONPG hydrolyzed = (OD a, 405 nm) * (final vol =1.92x 105 nl) = (OD4 05m) * (42.667 nmole)
(4500 nl/nmole-cm) * (1 cm)
The data from the experimental wells was normalized by subtracting the amount of
3-galactosidase activity in un-induced wells. To report percent of 3-galactosidase activity, 100%
[3-galactosidase activity was defined as the activity of induced cells, while 0% activity was
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defined as the activity of un-induced cells. Subsequently, all experimental data is reported
relative to these two controls.
High Throughput Screen
A-a 97Q cells were seeded on 96-well plates at 10 x 104 cells per well in 200 p1 of media
without selection drugs. In order to induce the expression of the P3-galactosidase A and a 97Q
constructs, PonA was added to a final concentration of 3 p.M. 5,000 compounds from Maybridge
were dissolved in DMSO and screened at 5-10 jiM concentrations, in triplicate. Eight wells were
used as positive controls and did not receive any compounds, and eight wells received un-
induced cells to determine 3-galactosidase background activity level. The screen was performed
at MIND CAGn by Deb Russel and Steven Altman, supervised by Aleksey Kazantsev.
Western blots
StHdh (Q 111/Q7) cells were seeded at 10 x 10 4 cells/ml in 12-well plates. Cells were
lysed in StHdh lysis buffer (20 mM Tris pH7.2, 150 mM NaCl, 1 mM EDTA, 1% Triton-X 100)
and Complete Protease Inhibitors (Roche), ice 30 min.
Lymphoblast cells were seeded at 10 x 104 cells/ml in 6-well plates. Cells were lysed
with Lysis Buffer (50 mM Tris pH8, 100 mM NaCl, 5 mM MgCl2, 0.5% NP-40) and Complete
Protease Inhibitors (Roche), ice 30 min.
Protein concentration was determined using Protein Assay and BSA standards (Bio Rad).
40-100 fig of protein in SDS loading buffer were loaded on an 8.5% low-bis acrylamide gel in a
PROTEAN II system (Bio-Rad), with P3-mercaptoethanol in the running buffer. Proteins were
transferred to PVDF (Millipore) using 10% MeOH in transfer buffer (25 mM Tris, 190 mM
glycine), at 25V 8 hr in 4°C.
PVDF blots were blocked in PBST with 0.5% milk for 1 hr. Actin (1:500, Sigma),
MAB2166 Htt (1:2000, Chemicon), or PolyQ (1:2000) antibodies were diluted in PBST with
0.5% milk and incubated for 2 hr at room temperature or overnight at 4°C. HRP-conjugated
secondary antibodies were diluted in PBST with 0.5% milk and incubated with blots for 30-45
min. Proteins were visualized with ECL Plus (Amersham Biosciences), and blots exposed to
MR film (Kodak).
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Figure 1: Distribution of 13 hits from HTS of 5,000 Maybridge compounds
d-a97Q cells were induced and treated with 10 uM compound for 24 hr. Compounds
were categorized by their ability to decrease Beta-galactosidase activity. Categories are
0-25%, 26-50%, 51-75%, and 75-100% Beta-galactosidase activity as compared to
induced cells without compound.
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Figure 2: Dose response curves for 3 Maybridge specific acting compounds
d-a97Q (diamonds) and d-a23Q (squares) cells were induced and treated with either
1, 2.5, 5, 7.5, or 10 uM compound for 24 hr. Y-axis indicates relative Beta-
galactosidase activity. X-axis indicates uM of compound. Error bars indicate standard
deviation. Asterisks indicate P<0.005 when compared to induced cells without
compound. N=2.
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Figure 3: Sample Wash-out experiment with A25
d-a97Q (A) and d-a23Q (B) cells were induced for 24 hr. The media from each well
was removed and replaced with either media with PonA (diamonds), media without
PonA (squares), or media without inducer but with 10 uM A25 (triangles). Beta-
galactosidase activity was assayed every 2 hr for 12 hr. Y-axis indicates relative Beta-
galactosidase activity. Error bars indicate standard deviation. N=5.
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Figure 4: Geldanamycin decreases Beta-galactosidase activity in both d-a97Q
and d-a23Q cells
d-a97Q (diamonds) and d-a23Q (squares) cells were induced and treated with either
1, 10, 50, or 100 nM geldanamycin. Y-axis indicates relative Beta-galactosidase
activity. X-axis indicates nM of geldanamycin. Error bars indicate standard deviation.
Asterisks indicate P<0.01 when compared to induced cells without compound. N=4.
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Figure 5: Sample Western blots of mouse straital and human lymphoblast cells
Lysates from StHdh 07/0111 (A) or various human Iymphoblasts (B, C) were run on
acrylimide gels and transferred to PVDF blots. A) PolyO antibody recognized full
length proteins. B) MAB2166 Htt antibody recognized full length htt proteins. C)
PolyO antibody recognized multiple Htt fragments.
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